

-----X
:
FIFRA SCIENTIFIC ADVISORY :
:
PANEL (SAP) OPEN MEETING :
:
-----X

METHODS USED TO CONDUCT A PRELIMINARY CUMULATIVE
RISK ASSESSMENT FOR ORGANOPHOSPHATE PESTICIDES

February 6, 2002

[8:30 a.m.]

SHERATON CRYSTAL CITY HOTEL
1800 Jefferson Davis Highway
Arlington, Virginia 22202

1 **PARTICIPANTS**

2 **FIFRA SAP Session Chair**

3 Ronald J. Kendall, Ph.D.

4

5 **Designated Federal Official**

6 Mr. Paul Lewis

7

8 **FIFRA Scientific Advisory Panel Members**

9 Herb Needleman, M.D.

10 Christopher J. Portier, Ph.D.

11 Stephen M. Roberts, Ph.D.

12 Mary Anna Thrall, D.V.M

13

14 **FQPA Science Review Board Members**

15 John Adgate, Ph.D.

16 William Brimijoin, Ph.D.

17 Richard Bull, Ph.D.

18 Rory Conolly, Sc.D.

19 Patrick Durkin, Ph.D.

20 Natalie Freeman, Ph.D.

21 Jean Harry, Ph.D.

- 1 Steven Herringa, Ph.D.
- 2
- 3 Ernest McConnell, D. V.M.
- 4 Peter MacDonald, D. Phil.
- 5 Nu-May Ruby Reed, Ph.D.
- 6 Lorenz Rhomberg, Ph.D.
- 7 Lauren Zeise, Ph.D.

1 DR. KENDALL: Good morning, this will convene the meeting
2 of the FIFRA Scientific Advisory Panel to continue our discussions on
3 methods used to conduct a preliminary cumulative risk assessment for
4 organophosphate pesticides. My name is Ron Kendall. I'm the chair
5 of the Science Advisory Panel and will be chairing this session.

6 I'd like to again thank EPA for being ready, and I thought we
7 had an excellent and productive day yesterday. And I'm looking
8 forward for the continuation of our discussion today.

9 We have several new panel members that are seated; therefore, I
10 will, as a matter of protocol, ask the Panel to reintroduce itself in
11 total. I'd like to begin on the far right and then move around. And,
12 please, for the record, state your name, affiliation, and expertise if you
13 would briefly.

14 DR. CAPEL: My name is Paul Capel. I'm with the US
15 Geological Survey Water Resources Division. My expertise and water
16 chemistry for the drinking water exposure part.

17 DR. ENGEL: Purdue University. My expertise would be in the
18 hydrologic water quality modeling area.

19 DR. BULL: I'm Dick Bull with Washington State University.
20 I'm a toxicologist.

21 DR. DURKIN: Pat Durkin with Syracuse Environmental

1 Research Associates. I am a risk assessor and I've worked with the
2 Agency in development of methods for mixtures risk assessment.

3 DR. HARRY: Jean Harry, National Institute of Environmental
4 Health Sciences in North Carolina. My research area is in
5 neurotoxicology.

6 DR. CONOLLY: Rory Conolly, CIIT Centers for Health
7 Research in Research Triangle Park, North Carolina. I'm interested in
8 mechanisms of toxicity and risk assessment.

9 DR. RHOMBERG: Lorenz Rhomberg, Gradient Corporation,
10 and also the Harvard School of Public Health. I'm interested in
11 quantitative risk assessment methodology.

12 DR. MCCONNELL: Gene McConnell. I'm a veterinary
13 pathologist-toxicologist. My area of expertise is in the design,
14 conduct, and interpretation of animal bioassays.

15 DR. ROBERTS: Steve Roberts; toxicologist; University of
16 Florida.

17 DR. PORTIER: Chris Portier, National Institute of
18 Environment Health Sciences in Research Triangle Park, North
19 Carolina. I direct the environmental toxicology program and manage
20 the national toxicology program. My area of expertise biostatistics
21 and risk assessment.

1 DR. ZEISE: Lauren Zeise, Kelly P. Office of Environmental
2 Health Hazard Assessment. My expertise is in risk assessment.

3 DR. RICHARDS: Pete Richards, director Of the Water Quality
4 Lab at Heidelberg College in Ohio with expertise in exposure patterns
5 in agriculture systems in the upper Midwest and the statistics applied
6 to those.

7 DR. ADGATE: John Adgate, University of Minnesota School of
8 Public Health, exposure analysis and risk assessment.

9 DR. REED: Nu-May Ruby Reed, California Environmental
10 Protection Agency, Department of Pesticide Regulation. I do
11 pesticide risk assessment.

12 DR. FREEMAN: Natalie Freeman, Robert Wood Johnson
13 Medical School and the Environmental and Occupational Health
14 Sciences Institute in Piscataway, New Jersey. Residential and
15 children's exposure.

16 DR. MACDONALD: Peter MacDonald from the Department of
17 Math and Statistics at McMaster University in Canada. General
18 expertise in applied statistics and model fitting.

19 DR. HEERINGA: Steve Heeringa, the Institute for Social
20 Research at the University of Michigan. I am a biostatistician. My
21 specialty is in population-based research.

1 DR. KENDALL: I'm Ron Kendall from Texas Tech University.
2 I direct the university's Institute of Environmental and Human Health.
3 My area of expertise is in environmental toxicology and risk
4 assessment.

5 I'd like to now introduce our designated federal official from
6 EPA, Mr. Paul Lewis, for any administrative procedures that he needs
7 to inform us on to get going today. Paul.

8 MR. LEWIS: Thank you, Dr. Kendall. And again thank you
9 again for agreeing to serve as our chair for this challenging and
10 interesting meeting over the next four days with our Scientific
11 Advisory Panel. I want to thank the members of the panel to agreeing
12 to serve and we're looking forward to your upcoming deliberation and
13 challenging discussions beginning with what we had yesterday and
14 carrying on today and beyond and for new members that have joined us
15 this morning for discussion on vary exposure considerations.

16 I want to remind everyone again that this meeting follows of the
17 guidelines of the Federal Advisory Committee Act. This is an open
18 meeting. There's an opportunity for public comment. All the materials
19 for the meeting will be available in a public docket. In addition, the
20 primary background materials and our subsequent report that serves as
21 meeting minutes for discussion during this week will be available in

1 the docket edition on our SAP web site.

2 Thank you again. I'm looking forward to both a challenging and
3 interesting over the next few days. Dr. Kendall.

4 DR. KENDALL: Thank you, Paul. Yesterday was a very
5 aggressive and forward-looking day. We actually got much further
6 than we thought we would. Therefore, today, we are at the point of
7 assessment of food exposure in terms of Session 2 as we continue our
8 review.

9 Dr. Perfetti, would you like to introduce your group or
10 Margaret, either one of you?

11 DR. PERFETTI: Thank you, Dr. Kendall. First of all, I'd like
12 to welcome the panel to today's session on food and drinking water.
13 And again I would like to thank the panel for all your valuable past
14 advice on the total assessment as well as yesterday's very interesting
15 discussion on hazard and dose response.

16 For the food presentation, Dr. William Smith, sitting to my left;
17 and Dave Miller will provide that presentation on food. Presentation
18 on water will be performed by Kevin Costello and Nelson Thurman.

19 I have a few points that I'd like to make, Dr. Kendall, before we
20 continue.

21 DR. KENDALL: Very well.

1 DR. PERFETTI: As mentioned yesterday, we intend to address
2 all of the points brought up yesterday during the public comment
3 period. We intended to address many of those points anyhow in our
4 presentation; but we have modified them such that we think we will be
5 able to speak to all of them.

6 To that end, we heard yesterday that OPP would be receiving an
7 OP cumulative assessment using the CARES software. OPP has also
8 contracted the Lifeline Group to perform a cumulative risk assessment
9 for the organophosphate pesticides.

10 This project has three components. The first is to modify the
11 Lifeline version 1.1 software as required to allow estimation of
12 cumulative exposure and risk for the organophosphate pesticides. In
13 addition to modifying the software, Lifeline Group will perform a
14 cumulative risk assessment for the OP and revise the user and
15 technical documentation to the Lifeline model so that it can be used by
16 all of the risk assessment community. We have done this in order to --
17 basically, we thought ahead. We did this in order to have yet another
18 software package for cumulative risk assessment.

19 And, finally, I cannot stress strong enough that OPP has no
20 intention of exclusively endorsing a particular model for estimating
21 pesticide exposure and risk. We'll accept any and all risk assessments

1 conducted in accordance with EPA and OPP guidelines and performed
2 with an appropriately peer-reviewed model. That can never be
3 stressed more strongly or often enough.

4 Thank you, Dr. Kendall.

5 DR. KENDALL: Thank you. Well, at this point, we can begin.
6 Let's go ahead and begin the presentation. Dr. Smith.

7 DR. SMITH: Good morning. This is an outline of what I plan
8 to discuss today. I want to cover three general areas in this
9 discussion. First, I would like to summarize the exposure inputs to the
10 cumulative food assessment. This includes the residue data, primarily
11 from the PDP monitoring program for food consumption data from the
12 USDA continuing survey of food intakes by individuals.

13 Secondly, I'll briefly review the residue adjustments involved in
14 the cumulative assessment. These are fairly simple calculations
15 compared to what we dealt with yesterday. This involves a conversion
16 to index equivalent residues, that is, methamidophos equivalence, the
17 relative potency factor method.

18 And then last, we'd like to review the preliminary assessment as
19 published in December which is a probabilistic exposure risk
20 assessment using the DEEM software.

21 Also, I will include some analysis of the important assumptions

1 that were incorporated in the exposure calculations and the beginnings
2 of the analysis of important contributors to the exposure distribution.

3 Essentially, all the residue data that we used in this assessment
4 are from the PDP Program. We, also, considered FDA monitoring
5 data, but this was primarily as background. There were only very
6 limited uses of it on a quantitative basis. All of these data are
7 available on the internet at these Agency's internet sites.

8 The OP active ingredients that are included in this assessment
9 are all included in the PDP monitoring program. What you see here
10 are essentially the parent active ingredients. PDP also analyzes for
11 important metabolites of these chemicals and degradates. And they
12 are also included in the assessment. I think between the span of 1994
13 to 2000, PDP has done significant analysis on maybe 70, or
14 approximately 70, OPs, either parent active ingredients or metabolites.
15 The extent of how we use these data are the extent of the availability
16 as well as how we use is available in our preliminary document in the
17 appendices.

18 We do not include cancelled uses in the assessment nor do we
19 include violative residues. Now these are tolerance-exceeding
20 residues or residues from nonregistered uses. Violative residues are
21 generally infrequent and for the most part at low concentrations. And

1 both PDP, our primary source, and for that matter, an FDA data,
2 which is designed to enforce tolerances.

3 I do not have an exact accounting of our the effect of our
4 omission of these violative residues. But it will be available with the
5 final assessment. But I can offer some general statistics.

6 In the most recent PDP data, tolerance-exceeding residues are
7 on the order of .2 percent of the analyses. And residues from
8 nonregistered uses account for a little bit over 1 percent. The FDA
9 monitoring, which one would expect to have more violative residues
10 since it is designed to analyze raw commodities close to their source,
11 has a little bit more. It has with domestic, approximately 1 to percent
12 violative residues; and import, closer to 4 press.

13 So for just as a general background response to public comment
14 about this, that is what we generally see in all the monitoring data.
15 Also, the data bases that are available on the internet from these
16 agencies as well as our data -- let me retract that. Our data do not
17 flag the violative residues, but the data bases as available from USDA
18 and FDA do. So one can easily pick out of the residues. There is a
19 field in the data base that identifies these.

20 There has been approximately 50 different foods that have been
21 analyzed in the PDP Program since 1994. And this is, of course,

1 counting some processed forms such as canned, frozen, this sort of
2 thing. All of these foods are included in the assessment. But some
3 specific chemical commodity combinations have been excluded to
4 account for cancellations or tolerance revocations and phase outs of
5 uses.

6 The residue data for these foods as supplied by PDP have been
7 adjusted by processing factors where suitable to include all the related
8 food forms found in the CSFII survey. Again, for example, using a
9 raw commodity with a processing factor to estimate residues on a
10 cooked, canned, frozen form, possibly a juice or dried form.

11 These data were extended to the extent possible by translation.
12 And in this case, it was done to food crops that had similar use
13 patterns. I will come back to these crops a little later in the discussion
14 of the preliminary assessment.

15 These are based on SOPs that we have developed for single
16 chemical assessments, and they are limited to crops for which use
17 patterns are similar. So we don't translate a chemical that would not
18 be appropriate to the other commodity.

19 Although, we primarily use FDA's background, there are some
20 exceptions. Eggs and seafood were included in the assessment. And
21 in both cases based on a long history of analysis by FDA with

1 negligible appearance of OPs. It was our judgment that we could
2 include these in our assessment as negligible residues.

3 Also, we included, based on the FDA total diet study, which is a
4 study -- the available data now on the internet goes through 1991 to
5 1997. These are market basket analysis -- actually, at-the-plate
6 analyses of prepared foods. Based on these assessments, it was our
7 professional judgement that we could include an estimate in our
8 assessment for the meats: Beef, pork, sheep, and goats. This is an
9 conservative estimate of residues based on the maximum values
10 determined from the total diet study. It's the only exception in the
11 assessment in which we use what one may consider a default
12 assessment. As it turns out, we have seen no real impact of this on the
13 total assessment. These values are still very low.

14 There are some other foods that were assumed negligible,
15 although we did not have extensive monitoring data. These are sugars
16 and syrups that are highly processed and refined. Based on that fact
17 alone with information we have on related commodities, led us to
18 conclude that we would not expect OPs to be present in these. So they
19 were included as negligible in the assessment, also.

20 Now, as a means of getting one perspective of assessing what
21 portion of the diet we're covering by these data that I've just

1 summarized, we ranked the foods as consumed by children from the
2 CSFII survey on a per capita basis in a descending order. And then for
3 each food we assigned it a percent value based on the total
4 consumption.

5 And what I have here in the table is an indication of what
6 proportion of the per capita consumption is covered by the things I
7 just summarized.

8 In this case, the PDP data, both of the raw commodities and any
9 processed commodities that we translated these data to, account for
10 approximately 86 percent of the diet. The translation that indicated, I
11 showed you, about 20 different crop names up there, account for only
12 1.3 of the per capita consumption. The data, the FDA-supported data
13 on eggs and fish and meat, account for approximately 6 percent of per
14 capita consumption.

15 Our assumption of negligible for sugars and syrups is another 3
16 percent. And this leaves approximately 4 percent of the food per
17 capita consumption that we have not included in the assessment.

18 Again, with this ranking of foods for children three to five in
19 this case, the top 30 foods in this ranking are included in the
20 assessment. And the top cumulative 95 percent of this diet that is
21 comprised of 556 foods, of 52 those are included. The ones I excluded

1 are dried beans, some corn-processed commodities and onions.

2 Other foods. Those and the other foods that are not included,
3 we do not expect to impact significantly on the assessment; although
4 we do have means to still test this and it is ongoing. Many of these are
5 highly processed or blended foods; therefore, you wouldn't expect to
6 have very high levels of these chemicals. And based on FDA data and
7 chemical registration data, we believe that all these would have
8 infrequently detected residues or low levels.

9 Moving on now to the residue adjustments. We're all familiar
10 with our way of dealing with exposure and risk here. We talk in terms
11 of margins of exposure, which would be a point of depart divided by
12 an exposure. The point of departure is in this case is a benchmark
13 dose 10. The exposure, of course, is composed of residue and
14 consumption.

15 The residues for this assessment are the cumulative residues.
16 We can converted chemical-specific residues on food samples to a
17 common residue. And this is an index-equivalent residue. This was
18 done on a sample-by-sample basis.

19 So an index-equivalent residue on a given PDP sample would be
20 estimated by multiplying that residue value by any applicable
21 processing factor and by its relative potency factor -- its potency

1 relative to methamidophos. And these residues would be summed for
2 each sample to become the cumulative residue in terms of
3 methamidophos.

4 Then these cumulative residues become inputs for the
5 assessment. Either as distributions of cumulative residues with each
6 number in the distribution representing a PDP sample or average
7 cumulative residues for some highly blend foods.

8 For our consumption modeling we used the CSFII, years '94
9 through '96 as supplemented in 1998. There are over 20 thousands
10 participants in this version of the CSFII. The surveys were conducted.
11 It was 2 days that were approximately 3 to 10 days apart. And this
12 does contain a 1999 supplemental children's survey where an
13 additional 5,500 children from birth to nine years old were included.

14 This survey is a significant increase for the number of children
15 as compared to the '89-'91 survey which we have been using at OPP
16 for you all of our single chemical assessments to date. This is
17 illustrated in this table which compares the number of children of
18 various age groups between the '89 to '91 data and the more recent.
19 You can see, for example, for children one to two, the number of
20 individuals is increased from 574 to 2,179.

21 The assessment, as currently published, includes four population

1 groups. Other age groups can be assessed easily, but none has
2 exposure estimates that exceed these groups we have. And the
3 children one to two are the highest exposed.

4 The exposure assessment models that we're using in this
5 assessment are DEEM and Calendex. My comments are going to be
6 restricted to the assessments as conducted with DEEM. David Miller
7 will be discussing some issue after I'm finished that incorporating the
8 Calendex. And he will highlight differences at that time.

9 DEEM combines residue and consumption distributions in a
10 Monte Carlo-like procedure to produce a distribution of one-day
11 exposure and associated margins of exposure.

12 We're using the FCID version of DEEM, which has recently
13 been released. This uses EPA's food commodity and intake data base
14 and commodity definitions. This may lead to some confusion on the
15 part of one who is reading through our assessment as published
16 because this came at a fairly late date in our assessment. And you will
17 find that we are referring to food forms as defined in the earlier CSFII.
18 But when we get to the actual assessment, we translate these to the
19 FCID form.

20 And, of course, among the differences in these, that is, one
21 difference in this FCID version of DEEM is that foods do have

1 different codes and many of them have different names. There are
2 some separate breakouts, for example, commercial baby foods are
3 broken out for each appropriate commodity.

4 Another significant difference is that this version of DEEM uses
5 publicly available recipes for relating the foods consumed to the raw
6 commodities or the values that would be plugged into the for
7 estimating exposure.

8 So this is the preliminary assessment as published in December
9 the 3rd. And this plot is a representation of the entire distribution
10 from zero to 100 percent of the exposure distribution. The top line of
11 the graph represents the BMD10 of .08 milligrams per kilogram per
12 day. The bottom line represents a value that is one million times lower
13 than that.

14 And there are four populations on this graph. If we can move to
15 the next one. This focuses in on the top 10 percentile of the exposure
16 range. And from this, I think you can begin to see that children one to
17 two are the most highly exposed population group. And then with the
18 specific numbers broken out for these four populations between the
19 90th and 99.9th percentile.

20 By June of this year we expect to have completed all the
21 refinements of the preliminary assessment and this includes, of course,

1 consideration of all the public comments as well as some QA on our
2 own part, changes we know need to be made. So this is very -- we're
3 very actively pursuing this.

4 We, also, have been conducting sensitivity analysis to gauge the
5 relative importance of the assumptions that have gone into the inputs.
6 We first revealed some of these in the case study that we presented to
7 the panel in December of 2000. And in principle, our results have not
8 changed from that in terms of the validity of those assumptions as we
9 tested them. And we're, also, beginning the process of the
10 interpretation of the results.

11 So next. Could you go back one. So, first, I would like to
12 show you a few results looking at the potential effects of input
13 assumptions and refinements on the assessment. Look at the effects of
14 translation of PDP data to other foods using processing factors to
15 estimate residue.

16 These data on this slide if you recall I showed you about 20
17 foods for which PDP data were translated because we feel they have
18 similar use patterns. And, of course, this is subject to question
19 always. This is a test of just what effect -- if we were making wrong
20 assumptions, what effect this would have on our assessment. And this
21 somewhat confirms our rankings that we had from the per capita

1 consumption, too, the foods to which we translated make up a relative
2 small proportion of the consumption and the total exposure. At the
3 higher percentiles, there is very little difference in the assessment if
4 one removes the assumption of OPs from all the translated foods. And
5 that's what this represents.

6 We have a particular case here of a translation of data to a
7 process commodity. In this case, we do not have processing factors or
8 other information input into the model for conversion of OPs from the
9 raw commodity to the baby foods. And, of course, we wanted to test
10 and see how this assumption could effect our end result.

11 And with the new version of DEEM, one can selectively remove
12 the contribution from all the baby foods. We did this for children one
13 to two. And it confirms that there is essentially no effect on the
14 assessment. This is probably not totally unexpected.

15 We, also, have done the same thing for children less than one.
16 And there is no effect because they eat more baby food. However,
17 children less than one as a group have a lower exposure than children
18 one to two.

19 This is somewhat of a boundary on all of our processing and
20 other extrapolations that we made. In this case, the top line, the top
21 row, is the full assessment. And the other row of information

1 indicates that a similar assessment in which we removed all translated
2 commodities and all extrapolated data so the only information, the
3 only OPs incorporated into the assessment, are directly related to PDP
4 analyses.

5 So there are no assumptions of processing factors; there are no
6 processed commodities unless PDP analyzed that processed
7 commodity. And there were no translated crops. And we felt this was
8 interesting to just sort of set a boundary on what we could expect to
9 accomplish with a number of refinements that we want to make to
10 these assumptions.

11 This is the previous slides in a graphical form the top 15
12 percentile of exposure. The top line represents the full assessment
13 and, also, coinciding on it in this scale is using only not translating to
14 other crops. And the lower lines represents removing all
15 extrapolations.

16 Now, we gave you a revised question, one for food. This is
17 partially the result of the limitations in time we have in doing some of
18 these analyses. And we were working on this part of the assessment at
19 the time we submitted the question. Based on the complexity of what
20 we were getting and the fact we did not have time to finish some of the
21 analyses, we choose to focus on some later things we're going to show

1 you. But I wanted to show you this anyway because it has come up
2 and it has been put on the internet.

3 In this case, we have questioned all along what the impact might
4 be of the fact that our PDP data ranges in the time frame of 1994 to
5 the year 2000 now. That's approximately seven years of data. Some
6 of the information comes from only the earlier portion of that time;
7 some from the later; some is spread across the seven years. We have
8 as little as one year of data for a food and as much as five years. We
9 wanted to evaluate the later data to see if they better represent the
10 current use practices.

11 This is incomplete; but at least in terms of an assessment, I can
12 show you how removal of older data, to the extent that only the most
13 recent two years maximum was included for any given food, has some
14 effect on the upper portion of the distribution. Maybe not a dramatic
15 effect, but it is shown in this slide.

16 So this analysis is not complete. We need to carefully look at
17 use pattern changes that have accompanied this. And we can, also,
18 look at specific chemicals that were removed by removing the older
19 data. So these are complex factors. We know, we did know, we were
20 working with multiple distributions representing different segments of
21 time.

1 Now for the final portion of this, I'd like to briefly summarize
2 our progress so far. I want to first qualify this by saying that we are
3 beginning to analyze critical exposure contributors; however, we're
4 doing this on the preliminary data. So for this reason, although the
5 process is of interest to us and we want as much input that we can get
6 on this process and how we can interpret it, the actual results that
7 we're getting at this point we're sure may be subject to some change;
8 therefore, we're going to speak in terms of pseudonyms again. I
9 apologize for that.

10 This case we were looking at -- could you back up one? I
11 should point out that the DEEM software has a critical exposure
12 commodity analysis incorporated in it. This is a means of looking at
13 the top much as 5 percentile of exposure to get an idea of which food
14 commodities are food are contributing, which food consumptions are
15 actually contributing to that part of the distribution. And we're
16 looking at this to get some idea of which foods and, also, which
17 chemicals are important. And we also, by keeping track of our sample
18 analysis on a sample-by-sample basis, we also have a history on all
19 these numbers. So we can go back and actually get sample details,
20 such as the origin, whether it's domestic or import data and whether
21 sample was taken in 1994 or the year 2000.

1 So working with the preliminary results and looking at, in this
2 case, we're looking at the area of the distribution between the 99.8th
3 percentile and the 100th percentile of exposure. And the critical
4 commodity exposure element does give you a listing of sort of a
5 descending ranking of foods that are contributing to that portion.

6 And over in this range, under the conditions of our run, which,
7 again, are preliminary, we had over 60 percent of the contribution to
8 this area was coming from three foods in all their forms. This could
9 include the raw commodity; it could include juices, dried forms,
10 sauces. It's three food crops that are contribution to this. And we
11 examined the impact of removing these residues from the assessments
12 to see how this may impact the upper part of this distribution.

13 Again working with children one to two, we looked, we
14 compared the full assessment. Two runs in which we removed singly
15 each one of the foods. Food A was the most abundant in this part of
16 the distribution. And if you remove only Food A, that second row
17 illustrates what effect that has on the distribution at the higher end.
18 Removing only Food B, there's less of Food B; the effect is less. And
19 same sort of thing with Food C.

20 Taking both A and B out, again, depending on one's perspective,
21 probably not a lot of change. It required removing all three foods in

1 all their forms to affect the change at the very top end of the
2 distribution of a two-fold change.

3 And this is just illustrating graphically what we have here that
4 as you go toward the lower parts of the distribution, effects can be
5 observed. But at the very top end of the distribution, it's difficult at
6 times to tell the significance of the differences.

7 And, again, just another way of looking at this. Also, I've
8 included the 50th percentile here which may not be in your background
9 materials. Just comparing the ratio of the MOEs at these different
10 points in the upper part of the distribution, you can see that the upper
11 portion of the exposure distribution is not affected very dramatically
12 by removing of these major contributors singly. And, again, to get a
13 two-fold change, required all three.

14 So our interpretations of the risk results are a little premature
15 to do that. But we do conclude at this point, that the PDP residue
16 data do cover the major food consumption items. We, also, based on
17 what we have so far, further refinements of the PDP data are not likely
18 to drastically alter the results at the higher end of exposure
19 distribution. And a rather nebulous conclusion here: Complex factors
20 are contributing to the exposure distribution.

21 There was, also -- if you back up, there's also a calendar-based

1 exposure which we used for food as well as the other pathways of
2 exposure. And David Miller will discuss that next.

3 So now I think probably that ends my part of the presentation.

4 DR. KENDALL: Any points of clarification? Thank you, Dr.
5 Smith. Very good. Any points of clarification from the Panel before
6 we move to the next section? Dr. Bull.

7 DR. BULL: This last piece is a little counter-intuitive to me;
8 maybe not to others. I think you were saying is the higher the
9 exposure, the less able you're able to account for causing that
10 exposure. That's my interpretation of what you're saying. I would
11 have thought -- and just to give you a minute to think -- that
12 something would be driving that very high exposure and that's not
13 what you seem to be ferreting out of that data.

14 DR. SMITH: In a sense, that's what we're asking you is how do
15 we interpret these results to help us however you can. As you go to
16 lower parts of the distribution, of course, the total exposure is
17 decreasing to very low values. So for that reasons, there's not much
18 difference.

19 DR. KENDALL: Go ahead. Dr. Portier.

20 DR. PORTIER: Following up on that same question, it seemed
21 to me that there's two possibilities for what could drive these margins

1 of exposures and reducing them for single commodities. One is the
2 commodity which very seldom has an OP level in it, but that OP level
3 is rather high when it's in there. That would contribute to the high end
4 of the tail of the distribution.

5 The other possibility is a commodity that has a fairly common
6 OP contamination in it but at a lower level. And it seems to me the
7 analyses you focused on for the commodity here is to find the rare
8 events. Did you know that when you went into that, or have you
9 thought about looking at reducing the entire distribution by finding
10 potential commodities that have low levels by consistently there?

11 DR. SMITH: Yes, we have thought about that. And there is a
12 companion part of this output from the DEEM in that you actually see
13 those highest exposure events. What I was talking to you about was a
14 summary of these highest events. And but we can also pick out the
15 actual food consumptions that contain the highest residue or the
16 highest consumption value. And we are trying to compare those. And
17 it is a little less straight forward.

18 At this point, we can't say much beyond what we've done -- it is
19 easy to pick out the top foods, you know, the ones that are coming to
20 the top of the assessment. And they of course, you're right. There is a
21 combination of having and some of them have a high percentage of

1 residues and/or high residues. Both factors are there. In addition, of
2 course, to whether it's a high consumption or not.

3 DR. KENDALL: Dr. McConnell,

4 DR. MCCONNELL: Two questions. First, are we are allowed
5 to ask what A, B, and C are? Oh, we have to go to the top.

6 MS. MULKEY: We made a judgment that we could obtain the
7 science thinking about this without identifying at this stage.

8 DR. MCCONNELL: Well, sure.

9 MS. MULKEY: Because there is a real market place, we
10 thought it was prudent we get the benefit of an enhance understanding
11 of the science before we did that.

12 DR. MCCONNELL: I guess the PC cops are out today.

13 What has been your experience over the past seven years? Have
14 the percentages of exceedence been going up or down, or finding that
15 in the particular commodity has it been increasing or decreasing with
16 time for the, if you will, for the problematic commodities?

17 DR. SMITH: Exceedence, well, there's exceedence of
18 tolerance.

19 DR. MCCONNELL: Maybe I didn't use the right term. I think
20 you know what I mean.

21 DR. SMITH: Yeah, you mean just the occurrence of these.

1 DR. MCCONNELL: Yes.

2 DR. SMITH: In general, the terms are hard to pick out based
3 on the information we have, but there is a decrease. So from 1994
4 through the year 2000, one can see the appearance of a decrease of
5 occurrence. This is -- I hesitate to say that that's a fact because this is
6 being observed without extensive statistical analysis. And of course,
7 we are interested in that and part of our goals are to decrease the
8 levels on foods.

9 DR. DURKIN: You have identified the top three foods. You
10 have, but we can't know it. What about the top three chemicals? Is
11 there a parallel analysis where you look at it by chemical over the total
12 diet so you can identify the chemicals that are there?

13 DR. SMITH: We are also looking at the chemicals in these top
14 foods, and we can track that because of the way we did the
15 distributions. We kept it tied to a PDP sample ID. And we do know
16 the processing factors and the origins of the samples. And in these
17 three chemicals -- I can say there are more than three chemicals
18 involved in those three foods; yes.

19 DR. DURKIN: I just want to be rear clear here. There could be
20 a parallel analysis where essentially you could spit out a vector of the
21 chemicals combined over the total diet. So if we wanted to identify, as

1 I'm sure you do at some point, what are the specific chemicals that
2 contribute most to risk and how is that laid out? Is that possible with
3 the software you have now?

4 DR. SMITH: Yes, it is. That is also underway. I choose not to
5 discuss it. We can selectively remove a given chemical's contribution
6 from the cumulative assessment. We can do it for a given food
7 chemical combination or just across the board. And that's also
8 actively in progress. But I just don't have -- I don't have any anything
9 really to relate to you on that at this point.

10 DR. KENDALL: Dr. Rhomberg. Dr. Durkin, any further
11 clarification? Dr. Rhomberg.

12 DR. RHOMBERG: I'm stepping a little bit out of my realm of
13 expertise here. It seems to me that one could say that it could be that
14 all sort of common diets are the same and every eccentric diet is
15 eccentric in its own way. So that might say that it would be a mistake
16 to focus on the single chemical or single food that causes the biggest
17 contribution to risk if that's something that's ubiquitous and
18 unavoidable.

19 It's sort of raising the baseline for everybody. And then the
20 people that have various odd combinations of things, which would be
21 very different for each of the different people, are the things that are

1 causing peaks and throwing a certain individual into the tail of
2 distribution one way or the other. That would be very important to
3 know for risk assessment purposes.

4 Is there a single thing that you can do? Is the way to avoid
5 problems that are caused by single unusual events in people because of
6 an exceedence or very eccentric diet is the way to handle that,
7 lowering the level of everybody, sort of lowering the average level so
8 that the peaks don't go higher or to attack the peaks particularly?

9 As I say, this is out of my realm both from the point of view of
10 assessing diets and from risk assessment. But I think it would be
11 important to pull out those kinds of observations from these things.
12 So that in a way, when you're looking at the peaks, maybe the thing
13 isn't the biggest contributors; it's the ones that are most different from
14 the main stream of people farther down in the distribution and are
15 there consistencies there that can be got at.

16 DR. PERFETTI: Dr. Rhomberg, if I understand correctly, I
17 think what you're asking is do the peaks represent unusual
18 consumptions.

19 DR. RHOMBERG: Unusual consumptions or unusual residues,
20 whatever. Just things that are -- it's got to be unusual something
21 because there has to be some reason why they go up into the peak.

1 DR. BULL: Otherwise you wouldn't get that distribution that
2 we just talked about. I was right.

3 MR. MILLER: The CEC does print out essentially those
4 individuals in the upper tails of the distribution. It lists out the
5 consumption and lists out the residues associated with that. And what
6 we do is look through that and get an idea of what's doing it. Is it
7 unusual consumptions entirely by one commodity or unusual residues
8 or such. So that is something we do look into in evaluating these
9 things and judging their reasonableness.

10 DR. SMITH: You know, to not be totally precise in describing
11 this, it is a very complex and even some of our single chemical
12 assessments maybe were not that different in their complexity. But in
13 this case, we are -- we do have the overlapping situation of
14 distribution of consumption, a distribution of a variety of possible
15 chemical uses. So more than one chemical is involved. And there's
16 not necessarily a direct correlation between the frequency of
17 occurrence and the relative potency of that chemical because these are
18 all adjusted relative to methamidophos and we have a wide range of
19 potencies in the chemicals over a few orders of magnitude.

20 We have, to our way of thinking, a fairly complex overlay and
21 the possible time frame consideration, a possible, fairly complex

1 overlaying of potential distributions. And we are look thing for what
2 are the single things we can do to interpret what this means. And to
3 this point, it's not necessarily a single thing; it's a combination.

4 DR. KENDALL: Dr. Portier.

5 DR. PORTIER: I was going to try to clarify Lorenz's comment.
6 But I think it's more appropriate for a discussion later on.

7 DR. KENDALL: I agree. Dr. Heeringa.

8 DR. HEERINGA: I have a very quick question about the
9 mechanism of the simulation where you remove foods A, B, and C.
10 When you do that in the simulation, do you literally strike those foods
11 out of the sample child's diet; or do you sample children who consume
12 those foods on that day? In other words, is there a replacement of
13 other diets that's taking place in the simulation?

14 DR. SMITH: We're removing the OP contribution to that diet.

15 DR. HEERINGA: You actually sample the child. And if it
16 happens to be a contribution A, B, and C, so you're essentially
17 lowering an expectation the overall residue consumption.

18 DR. SMITH: Correct.

19 DR. KENDALL: Dr. Freeman.

20 DR. FREEMAN: Two things. When you did this, are you only
21 looking at commercially used pesticides as opposed to residential

1 fruits and vegetables that are treated? And the second thing is, a
2 number of these commodities, based on the data that we were provided
3 with, are produced in very specific regions. You know, they're either
4 warm weather crops or they're cold weather crops. And so you may
5 have three areas of the country that are generators of, say, one of
6 these crop items.

7 Have you looked at the differences in pesticides according to
8 the regions from which the samples were obtained? And have you
9 tried to do some sort of weighting based on some sort of distribution
10 across the regions as to how it's going to impact on the pesticides in
11 these foods?

12 MR. MILLER: The assumptions in this assessment is that PDP
13 does sample proportionate to a national basis proportionate to
14 production. So if 20 percent of crop A is grown in California, or
15 consumed in California, 20 percent of the samples would be from
16 there. So overall, on a national basis, yes, it is proportionate to that.

17 In terms of looking at regional residues, for example, we assume
18 essentially it's a national distribution of the commodity. So we don't
19 look at specific regions and don't look at specific residues in specific
20 regions.

21 DR. FREEMAN: Yeah. I'm a little concerned about that

1 because you see a constellation of pesticides in one region for say
2 apples that you may not find in another region that grows apples.
3 They have one or two that are the same, but there may be differences.
4 And that might impact your results.

5 DR. KENDALL: Dr. Adgate.

6 DR. ADGATE: I'm curious. What's the rationale for removing
7 the violative residues?

8 DR. SMITH: Should I pass that to the end of line or try it
9 myself?

10 MS. MULKEY: In pesticide regulation, there's always the
11 challenge of whether you regulate to violations or regulate on the
12 basis of the assumption that people comply with the law. It's not
13 unique to this situation. We face that issue a lot. And if we believe
14 that violations are endemic, that there's sort of an inherent aspect of
15 the lawful use, we will consider violative scenarios. I'm talking now
16 generally, not in this one. I think we do not have a basis in these
17 examples in believing that the violations predictable, sustainable, sort
18 of unavoidable by product of lawful use.

19 But if we did or had some basis to, then that would be the
20 situation in which would typically take into account violations. This is
21 not a policy we developed just for this approach. That's been our

1 longstanding approach to the way we thought about pesticide
2 regulations. And it involves not just foods but other exposure
3 situations, too.

4 DR. KENDALL: Dr. Portier. This is the last question.

5 DR. PORTIER: No, this is four or five. I was waiting to see if
6 anyone else would ask them. Again, hopefully, these are just
7 clarification questions. In what you just presented, those are single
8 day resamples for single-day diet; is that correct?

9 DR. SMITH: Yes. But it's using both days of the diet.

10 DR. PORTIER: Okay. I don't understand that. Run that by me
11 again.

12 DR. SMITH: They are single-day exposures, but they are
13 obtained by using a survey that is composed of two separate days.

14 DR. PORTIER: And in the two-day survey that you're using,
15 you're just using the one of the days as the resampling for food
16 consumption.

17 DR. SMITH: No, in DEEM, both days are used.

18 MR. MILLER: The count is separate. I'll get into it a little bit
19 in my presentation. The account is essentially separate people. In the
20 diet food Person No. 1, Diet No. 1, counts as essentially a separate
21 person than Diet No. 2 for that same individual.

1 DR. PORTIER: But you're sampling the day's diet.

2 MR. MILLER: Yes.

3 DR. PORTIER: For one of the two days by random draw.

4 MR. MILLER: Yes, yes.

5 DR. PORTIER: So that was the second part of my question.

6 There is a random draw for diet as well as a random draw for pesticide
7 residue.

8 MR. MILLER: Random draw. But the random draw for diet is
9 connected to that individual. Well, actually, I'll talk about it a little
10 bit more in my presentation.

11 DR. PORTIER: We talked about the violations issue. I wanted
12 to raise that again. I think you want to look that the policy, at least
13 try to collect some data on what percentage of violations are actually
14 caught.

15 The PDP data is market basket from food stores. Does it
16 include market places? Road-side buys? Anything like that?

17 DR. SMITH: PDP is primarily from food distribution centers.
18 It's not at the grocery store in general. In some commodities, for
19 example, some of the grains and I think maybe grains were taken from
20 a earlier point in the distribution, the idea was to get it as close to the
21 distribution as practical to be able to reproducibly over time go back

1 and resample.

2 DR. PORTIER: To follow up on that question we had a minute
3 ago, I didn't understand the resampling scheme. If I resample a diet
4 and the child gets two apples in one day, assuming apples may or may
5 not be exposed to OPs. But I'm going to choose apple for the fun of
6 it. Do the apples get two separate random draw residues independent
7 of each other, or do the two apples get the same residue?

8 MR. MILLER: In the DEEM, what it does is it totals it over the
9 day. So if your child has, the person you're drawing, has two apples in
10 one day, they will, essentially, be combined in consumption of grams
11 per kilogram. And then it will draw one random residue value for that.

12 DR. PORTIER: That basically assumes, I guess, the two apples
13 have the same residue which is fine for me.

14 And there was a another statement you made, and this is my last
15 question. When you looked at the population groups assesses and
16 noted that the children one to two years old have the highest
17 exposures of all these groups, I gather, because you did not show us,
18 you did not do less than one year and you did not do the other groups.
19 You are assuming that those other groups are not as high of an
20 exposure; is that correct? Or did you actually do the less than one
21 year olds?

1 DR. SMITH: We have done less than one and the exposure is
2 less. Some -- I mean the possibilities are, you know, you can go in
3 and adjust the years that you want to take. So there are a number of
4 possibilities. And at different stages in the assessment, we've looked
5 at other combinations. At this point, I cannot give you an assessment,
6 say, for children one to six all inclusive. We have three to five broken
7 out from one to two, and we have looked at less than one. We just
8 haven't included it.

9 DR. PORTIER: And do you intend to include that in the final?
10 We got several questions about that yesterday. And I'm trying to
11 understand why it's not in here then.

12 DR. PERFETTI: I mean, basically, not just this analysis, but
13 with a lot of them. One to two are the most highly exposed right down
14 across the line. We could put zero to one in or all the other age
15 groups, but it would always, be to our knowledge, and, Dave, I think
16 you can agree with me, it's always the one to two because they have
17 the largest consumption with respect to body weight. So they always
18 are going to get quote the "highest exposure". So if you know that
19 one to two are going to be the worse case, everything else, the
20 exposure is going to be less.

21 DR. PORTIER: I guess you can assume I'm from Missouri. I

1 like to be shown. "Show me" is the basic tenet here.

2 DR. KENDALL: Thank you. Any further points of
3 clarification? Dr. Zeise. Remember, Dr. Miller, we'll go forward and
4 probably clear up a lot of these questions. The presentation is quite
5 long so I didn't want to break in the middle, at least let people to have
6 a chance. So points of clarification.

7 DR. ZEISE: Yes. I was, also, wondering what the teenager,
8 the upper end might look like for teens. Just curious, looking through,
9 they're conspicuously missing. And I also wondered in terms of
10 thinking through what might be happening with the tail if you looked
11 at the issue of using composite sampling. What that would do is
12 you're smearing out and probably have more zeros, more cases of zero
13 and then higher values and that the composite sampling is actually also
14 doing some smoothing at that upper end.

15 DR. SMITH: Actually, we do have limited -- we do have
16 information from single serving versus composite samples. PDP has
17 looked at three different commodities: peach, pear and apples. And
18 there is also an industry market basket study that was done on
19 single-serving basis; although, they do not have a composite direct
20 comparison to a composite.

21 At this point we do not see a lot -- maybe surprisingly -- a lot of

1 difference between the distribution in the PDP between the single
2 serving and the composite.

3 DR. ZEISE: At that upper tail.

4 DR. KENDALL: Dr. Bull.

5 DR. BULL: Just a real quick clarification of Chris's. When you
6 looked at the less than one year old, is that distribution more or less
7 the same; or is the high end exposure still even more exaggerated?
8 When you say "across the board," I was trying to figure out what
9 across the board meant. Am I making myself clear?

10 DR. SMITH: I'm not sure I can give you correct answer on
11 that.

12 DR. BULL: Well, you have a curve that describes the
13 distribution of exposures in terms of MOEs, the fraction of the MOE.
14 Is that slope of that curve similar in the less than ones as it is to the
15 one and twos. I could see the extremes being more marked in that
16 group.

17 DR. SMITH: That's a good point. And I haven't carefully
18 looked at that. We do know that they are less exposed in terms of
19 comparing the curve shapes, we haven't gotten to that. But that is a
20 good point.

21 DR. KENDALL: Dr. Reed.

1 DR. REED: This is a quick clarification question. Because you
2 didn't see a great difference in residue distribution between
3 single-serving-size surveys and the composite samples, and that's the
4 reason you didn't use single-serving-size data; is that correct?

5 DR. SMITH: Yes. Possibly another reason. That's part of it.
6 And just the feeling that if we have this huge data base of composite
7 samples, and to use the single serving, we're limiting ourself to one
8 small segment of data. If it did not make a difference, the composite
9 samples, it would be consistent kind of analysis. We feel that
10 composite samples may be better suited for catch catching co-
11 occurrence. Can't prove that; but that's our general sense of it. That
12 would be another reason.

13 DR. REED: Thank you. The other short question is: There's
14 mention about choice years of PDP data. The analysis seemed to
15 indicate that maybe you don't need that many years of data. There's a
16 mention in the document about correlating that or the concern for pest
17 pressure. Have you gotten any chance to go back and sort of looking
18 backwards to see if there's any past pressure situation in that the PDP
19 data actually picked that up in terms of residue?

20 DR. SMITH: That's part of the analysis that led us to change
21 the question somewhat because we have not completed that. We are

1 interested in whether we can pull that out. We don't know.

2 DR. KENDALL: Any further comments related to this stage of
3 the presentation? Before we move to Mr. Miller, I'd like to welcome
4 Ms. Marsh Mulkey, the Director of Office of Pesticide Programs. We
5 appreciate you joining us again. Would you like to address the Panel?

6 DR. ADGATE: No thank you.

7 DR. KENDALL: Mr. Miller, are you ready to proceed?

8 MR. MILLER: Just to kind of go through quickly the outline of
9 the presentation. I'll provide an introduction, background
10 information. It will be a brief overview and recap of probabilistic
11 techniques used in preliminary cumulative risk assessment, or PCRA.
12 I'll then talk a little DEEM(FCID) versus DEEM(FCID)/Calendex. As
13 Bill had mentioned, his talk was on DEEM(FCID). And all the FCID
14 means is the new recipes, the new publicly available recipes and the
15 new '94, '96, '98 data. Do a little talk about the difference between
16 those two and how the one includes a time component.

17 I'll talk a little bit then about the time frame considerations.
18 Why it's important. There will be more details relating to this
19 tomorrow. Specifically, how to compare these with a tox endpoint.

20 Then talk about modes in which Calendex can be used for a
21 cumulative risk assessment which goes directly to the time frame

1 consideration issue. Consecutive daily estimates is one potential
2 mode. That was the mode that was used in the preliminary cumulative
3 risk assessment, PCRA, that provides separate estimates for January 1,
4 January 2, January 3, et cetera. And alternative, methodology, which
5 is available in DEEM which was not used for the December 3
6 document was rowing or sliding assume time frame approach. Again,
7 there will be a little bit of discussion of this in terms of interpretation
8 on this on Thursday.

9 And then going to strengths and limitation of these modes and
10 the associated issues. This will include a comparison of some runs
11 we've done comparing the 1-day assessment with the 7-, 14- and
12 21-day rolling averages. And you'll see those numbers here.

13 And then, finally, the questions for the SAP.

14 Just some points to remember, the presentation will not
15 extensively review the step-by-step mechanics of DEEM(FDIC)
16 Calendex algorithms. DEEM Calendex was reviewed in previous
17 SAPs. However, I will try to give you a flavor of what's happening.
18 And where it's important, I'll go into the details and differences
19 between the modes.

20 The main presentation, here, concentrates on exposures through
21 food. However, the principles apply to all routes. And, finally, I'll

1 remind you that no decision has been made on an appropriate MOE or
2 threshold percentile for regulation.

3 When I talk about X-percentile graphs, they are meant to be
4 illustrative only, intended to illustrate the concept. It's not that we've
5 made a decision or are leaning toward any specific percentile or MOE.

6 Just some background, DEEM(FCID)/Calendex provides
7 probabilistic assessment of exposures through food, water, and
8 residential pathways. DEEM(FCID)/Calendex incorporates the
9 concept of a calendar to aggregate or accumulate exposures -- it's a
10 time-based approach -- which allows us to look at individual days of
11 the year. Importantly, the approach allows appropriate temporal
12 matching of exposures through food, drinking water, and residential
13 pathways.

14 These temporal aspects are important for OPs to the expected
15 seasonal use patterns. For example, it would be important to match
16 springtime exposures from one applications through exposures through
17 drinking water associated with spring runoff. Likewise, it would also
18 be important to preclude or appropriately discount nonsensical or low
19 probability events, perhaps treatment of house for fleas during the
20 wintertime in the northeast.

21 So this is what Calendex allows us to do. Thus Calendex uses

1 probabalistic techniques to appropriately combine exposures from the
2 food, water, and residential pathways in a manner which incorporates
3 probabilities of exposure, use and application practices, human
4 activities patterns, et cetera. Importantly, it considers their
5 associated seasonality and timing.

6 So we expect, for example, probabilities of exposure, one can
7 input as a data for Calendex at maybe perhaps 6 percent of the
8 individuals users of a pesticide, or the 15 percent of apricots contain
9 residues. So the probabilities of exposures can be counted in that
10 way.

11 Use and application practices can also be accounted for. If the
12 label directions say apply in spring, then it will be applied in the spring
13 as per Calendex. If the label directions say, for example, or if we
14 know that 80 percent of the users apply it one time and 20 percent
15 apply a second application 2 to 4 weeks after the first, that
16 information can be incorporated as well.

17 It also incorporates human activity patters, time spent on lawn,
18 for example, time spent inside, et cetera.

19 The result of the result of the Calendex analysis is a collection
20 or distribution of aggregate exposures, that's food, residential and
21 drinking water combined, for each day of the year for the relevant

1 region. These exposures can be plotted as a time line or profile of
2 population daily exposures for any given percentile in this
3 distribution. This is illustrated on the next slide.

4 This is just a quick 3D graphic which kind of summarizes DEEM
5 Calendex output in a compact form. You can see the vertical axis is
6 the exposure. That's plotted against a time line in the bottom of
7 horizontal axis from zero or 1 to 365 days. And the depth is the
8 percentile for any given percentile. In other words, what we can do is
9 plot exposures as a time line against any given percentile.

10 The graph emphasizes an important point that a time line,
11 time-based profile exists for any selected percentile. We've shown
12 some specific ones here, 10, 30, 50, et cetera. For example, there's
13 one at 99 here which goes on. It goes along there from January 1 to
14 December 31. And what that does is it shows or plots out the 99th
15 percentile exposures for each of the 365 days of the year. 99th
16 percentile for January 1, 99th for January 2, et cetera.

17 The three 3D graph essentially summarizes output that's
18 specifics to DEEM(FCID)/Calendex as opposed to DEEM(FCID)
19 which Bill talked about. Again, you get the three-dimensional part
20 because of the time component is added here.

21 DEEM(FCID) analysis assess exposure from food alone, as Bill

1 said, without respect to timing or seasonality issues. What it does is it
2 randomly matches report food consumption by individual with residue
3 data. There's no time component to this. The result, as Bill described,
4 is a single distribution of exposures and a single value estimate of risk
5 at any percentile of exposure.

6 How does DEEM(FCID)/Calendex, which incorporates the time
7 component differ DEEM(FCID) when we do an aggregate or
8 cumulative assessment in which pathways are combined, time and
9 considerations become important? DEEM Calendex performs this
10 analysis in a manner in which time considerations are incorporated. It
11 does this by performing separate analyses for each day of the year.
12 The result is 365 separate distributions of exposures for each day of
13 the year. And exposures can be at any given percentile, 99th, 95th, et
14 cetera, can be plotted as a time-based exposure profile.

15 These differences are summarized on the next slide.
16 DEEM(FCID) considers food alone; whereas the
17 DEEM(FCID)/Calendex considers all pathways, food, water,
18 residential. Timing is not considered in DEEM(FCID). There's no
19 day-to-day variation, whereas timing is considered in
20 DEEM(FCID)/Calendex. There's some day-to-day variations in the
21 diet. That will be explained a bit later in this presentation.

1 And another difference is single-exposure estimate is provided
2 DEEM(FCID) at any given percentile; whereas,
3 DEEM(FCID)/Calendex provides 365 sequential daily exposure
4 estimates for any given percentile.

5 With that as background and the knowledge that
6 DEEM(FCID)/Calendex can consider time, there are several issues to
7 the SAP regarding time-frame considerations. Remember that
8 exposure's only half the risk equation. It's important to consider how
9 the estimated exposure is compared with the toxicity endpoint.

10 In the preliminary cumulative risk assessment, PCRA, toxicity
11 endpoint is based on the BMD10 which reflects a multi-day dosing
12 study or a series of multi-day dosing studies. And you heard about
13 this yesterday from Anna and Woody. You, also, heard about it last
14 September at the 2001 Scientific Advisory Panel meeting.

15 In the report you provided, there were two statements that
16 cumulative risk assessment should ideally compare toxicity endpoint
17 and exposure durations of the same time frame. And, also, to the
18 extent possible, comparison should take into account the pattern of
19 human exposure.

20 Again, you're scheduled to hear more about this comparison
21 tomorrow under the risk characterization session. But in my talk here,

1 what we'll focus on is the time-frame issue and how it's handled by
2 DEEM and Calendex.

3 DEEM Calendex program can perform analyses using a variety
4 of time frames. You heard from Bill the single day. This presentation
5 considers two specific modes of analysis which are available in
6 Calendex. One is the single consecutive daily estimates, January 1,
7 January 2, et cetera. That was the analysis that was used in the PCRA.

8 The second is a rolling or time-frame approach where it takes a
9 rolling average, considering, for example, January 1 through 7, then
10 January 2 through 8, then 3 through 9, et cetera. It provides an
11 average exposure over that time period.

12 I'll emphasize that the examples I'll give you here are
13 illustrative only, intended to illustrate the concept. The numbers are
14 not real. And PCRA used, again, the first option; the
15 single-consecutive day rolling estimate not the rolling time frame.
16 Although at the end of this presentation, you'll see those results for
17 the rolling time frame and be able to compare the two.

18 Just first option, the single-consecutive-day analysis, the
19 analysis we used in the December 3 assessment, provides separate
20 independent exposure and risk estimates made for each day of the
21 year. And I'll show this in the next few slides, summarize how that is

1 done.

2 The estimates, then, are arrayed chronologically into an
3 exposure time line for any selected percentile and graphed. These
4 represent independent daily estimates of risk on each day of the year.
5 Importantly, they're not necessarily -- as you'll see in the following
6 slides, they're not necessarily the same individual on consecutive days.
7 What I mean by that is the next several slides show how this is done by
8 DEEM Calendex.

9 So for a single-consecutive-day analysis, the analysis that was
10 done in the assessment, and, again, the numbers here are not
11 necessarily -- they're not necessarily the numbers. It's illustrative
12 only. What DEEM would do would begin with January 1.
13 DEEM(FCID)/Calendex begin with January 1, CSFII, Individual No. 1.

14

15 What DEEM Calendex would do would then estimate the
16 exposure and plot that exposure to the individual on the histogram.
17 So that could come across as -- essentially think of it as a first block
18 of a histogram would be located someplace along there.

19 How is that exposures estimated? It's done for that Individual
20 No. 1 on January 1. It's done by randomly choosing one of Individual
21 No. 1's self-reported diets and then randomly selecting a residue for

1 each component of that diet. And that is essentially summing them up
2 and estimating an exposure based on that.

3 And the same thing would be done with Individual No. 2. And
4 that would work out -- actually, if you could back up for a second.
5 That would be the same thing would be done for Individual No. 2.
6 And the result is a slowly build up essentially a distribution which
7 might look something this, a histogram with a shape that looks
8 something like that.

9 In this case then what we do is, if we were choosing to plot out
10 the 99.9th percentile, what we would do is estimate what that is. In
11 this case, it might be individual No. 10,456 that would plot out at the
12 99.9th percentile and essentially estimate the exposure from that
13 individual at that percentile. That might, for example, translate to a
14 MOE of 84.

15 We than move on to January 2 and do the same thing. Starting
16 with Individual No. 1, estimating the exposure and plotting. And,
17 again, we do it for all the individuals. Individual No. 1, 2, 3, et
18 cetera.

19 In this case, these would be plotted out for all the individuals.
20 In this case, the 99.9th percentile individual exposure might be
21 Individual No. 1,492. We estimate exposure. And that might work

1 out to be, for example, an MOE, margin of exposure, of 92.

2 We would proceed through each day of the year in this through
3 December 31, which is here. In which case of the 99.9th percentile
4 individual or exposure, might be Individual No. 18,912. again, we'd
5 estimate an MOE with that exposure.

6 The net result of this is we end up with 356 different 99.9th
7 percentile values. Again, what we've done is for each day of the year
8 we've run through each individual and we can pick out the 365th -- the
9 99.9th percentile values.

10 What we do is take each of these 365 99.9th percentile values
11 and then plot them out for each day of the year, January 1 through
12 December 31, that population percentile. The resulting time-based
13 exposure profile represents, in this case 99.9th percentile exposure for
14 each day of the year.

15 It's important to remember that each day of the year is
16 considered independently. It is not the same individual. If you
17 remember on January 1, it was Individual No. 10,456 that was at the
18 99.9th percentile. On January 2, it was a different individual.

19 One can see this plot on the next slide here. The vertical axis.
20 These plots are central to the understanding and interpreting the
21 cumulative risk assessment. I'll go through it in some detail.

1 Remember, this is the single day assessment as we used in the
2 preliminary assessment.

3 This is the vertical axis here. It's the exposure. Here is the
4 time line. The horizontal axis is the day of year from January 1
5 through December 31.

6 Continuing with the example, if you remember, January 1, the
7 99.9th percentile exposure value was associated with Individual No.
8 10,456. He had an MOE of 84. So that would be plotted here for
9 January 1.

10 For January 2, the 99.9th percentile individual, the value
11 associated with the 99.9th percentile exposure would also be plotted.
12 In this case it might be an MOE of 92. It continues through the year
13 through December 31.

14 Just some key points. These are all, again, each different
15 individuals. These are also one-day exposures.

16 How is this interpreted, for example? Day, for example, if you
17 wanted to interpret the MOE associated with Day 31, this would
18 essentially look up here, and this would be perhaps an MOE of 58.

19 How is that interpreted? On Day 31, the day we were looking
20 at, on the next slide, the MOE for food, the interpretation would be
21 the MOE for food at the 99.9th percentile would be 58. The

1 translation of that would be the exposure to the 99.9th percentile
2 individual on Day 31 is 58 times lower than the BMD10.

3 Day 32, it may be that the MOE was estimated as 66. The
4 translation of that would be that the exposure to the 99.9th percentile
5 individual on that day is 66 times lower than the POD. Remember, it's
6 very likely that that is a different individual than the 99.9th percentile
7 individual on January 31. Just as on January, the 99.9th percentile
8 individual was different from the individual on January 2.

9 The next slide shows some pros and cons of this method. This
10 was the method that was used in the PCRA. It's easier to identify risk
11 contributors and sort them out using the CEC function of DEEM.
12 That's the function that Bill had talked about some.

13 It's also health protective from a multi-day standpoint. When
14 one looks at a sustained or extended period of time of elevated
15 exposures, it's unlikely to be the same individual that's being exposed.

16 However, there are a number of disadvantages to this. One is
17 that the point of departure, the BMD10, is based on multi-day
18 exposures. The animals, if you remember from yesterday, are dosed
19 daily for an extended period of time to estimate the BMD10. It might
20 of be of concern would be the relevance of comparing a series of
21 elevated single-day exposures to a multi-day endpoint.

1 Another disadvantage is the second consecutive daily estimates
2 are likely to over estimate multi-day exposures to an individual at the
3 higher percentiles. For example, it's not possible to interpret an
4 extended series of elevated exposures on consecutive days as
5 representing extended period of exposure to the same individual. In
6 other words, we haven't strung together consecutive days for the same
7 individual. So the individuals are different.

8 If we were to string together consecutive days for the same
9 individual, what we'd get from DEEM we'll be able to have essentially
10 a rolling time frame approach. And this is what this next series of
11 slides considers. And I'll talk about stringing the days together and go
12 through a detailed example of how this is done.

13 It can, also, be looked at as essentially a multiple sequential day
14 option. In this rolling-time-frame option, a rolling average exposure
15 is calculated over multiple days for each individual. For example,
16 January 1 through 7, then January 2 through 8, and January 3 through
17 9, et cetera.

18 It's this series of multi-day average exposures that then serves
19 at a basis of comparison with the BMD10 -- with the POD. More,
20 specifically, this distribution of individual-based multi-day average
21 exposures is compared with a multi-day BMD10.

1 The next slide show an example of this. And, again, the
2 numbers are not real but are meant to be illustrative only.

3 Specifically, this specific example will deal with a 7-day rolling
4 average. It begins with individual No. 1 on January 1. And you can
5 see this is going to be this January 1 through 7 rolling average. This
6 exposure to this individual on January 1 is estimated from this DEEM
7 Calendex software as .012 milligrams per kilogram per day. That's
8 estimated, as always, by randomly choosing CSFII Individual No. 1,
9 Day No. 1 or Day No. 2 diet; randomly choosing residues associated
10 with each component of that diet; combining those; and summing them
11 over all foods reported consumed by that individual on that day. So
12 that point .012 is estimated in that way.

13 The same thing is done for that individual for January 2, again,
14 choosing one of his two randomly reported diets. And January 3, et
15 cetera, all the way through through January 7. You can see on January
16 2, the estimated exposure using that is about a little bit over .006.

17 The next step after that, after we've calculated exposure from
18 each of those days is to calculate an average exposure over the entire
19 full 7 days. Here the average exposure, you can see, is about .006
20 milligrams per kilogram.

21 We've done this then for Individual No. 1 for January 1 through

1 7. We now move on to Individual No. 2 for this same time frame.

2 Again, starting with January 1, estimating the exposure as before for
3 each day, January 1 through January 7. After that's done, we calculate
4 a 7-day average over this time period. Here you can see it works out
5 to be about .007 milligrams per kilogram.

6 We continue this through all individuals in the survey,
7 calculating it for January 1 through 7. If there were 15,243
8 individuals in the survey, for example for the last individual, the 7-day
9 average exposure works out to be .005 milligrams per kilogram.

10 If there were 15,243 individuals in the survey, we'd end up with
11 15,243 7-day average exposures for January 1 through 7. Then what
12 we would do is sort them from high to low and pick out this 99.9th
13 percentile exposure and plot this value for January 7.

14 So what we've done is for January 1 through 7, calculated for
15 each individual a rolling average and picked out the 99.9th percentile
16 values in this case just as an example.

17 For the next rolling time frame is January 2 through 8, we go
18 back to Individual No. 1 and calculate exposures for each of the days,
19 January 2 through 8, again randomly choosing each day one of his two
20 reported diets and combining it with a randomly selected residue. We
21 do the same with Individual No. 2, Individual No. 3, et cetera, for

1 January 2 through 8. Continue all the way through and then slide
2 along and do 3 through 9, January 4 through 10, et cetera, until we get
3 to this last individual which would be January 1 through 6. It rolls
4 around. We'd end up with 365 different 99.9th percentile 7-day rolling
5 average exposures and plot them over time as we did before.

6 There are a number of advantages and disadvantages to this
7 approach. One advantage is that it incorporates the variability in
8 exposure for an individual across multiple days. This multi-day
9 average exposure may be the actual exposure of interest to compare
10 with a multi-day endpoint.

11 It's also likely to provide a more realistic estimate of exposures
12 across multiple days. And, again, if it's not a series of single-day
13 exposures we're interested in, this allows us to calculate high end
14 multi-day average.

15 It's also flexible with respect to matching time frames
16 associated with the POD. One can chose, for example, this example
17 was 7 days. But one could chose 7-, 14-, 21-, or 28-day rolling
18 averages.

19 There are a number of disadvantages, too, to this approach.
20 Break down into two basic areas, one associated with food
21 consumption and the other associated with residue. UDSA, CSFII

1 does not provide consumption data across the multiple consecutive
2 days which would be of interest. It's limited to two days of records of
3 reported intake. Also, those two days are not consecutive. They are 3
4 to 10 days apart.

5 As a result, the multi-day average exposure for any individual
6 uses only two days of reported consumption data for that individual.
7 With the rolling average approach, what we're using is those two days
8 of reported intakes to simulate 7 or more days of eating. It repeats
9 these randomly throughout the time frame of interest.

10 The other aspect concerns food residues. There are no
11 longitude and residue data available. For example, if I ate a star fruit
12 yesterday and star fruit today, if they came from the same Safeway,
13 they're likely to have the same residues than if the one I ate yesterday
14 was from Safeway and the one I ate today was in the company
15 cafeteria. So there's no longitudinal basis on residues for that.

16 Just more specifically on those two points regarding, first, on
17 food consumption aspect. Any consecutive day period of interest for
18 an individual will contain a series of repeated diets which would tend
19 to underestimate the variability. This will tend to over state potential
20 exposure at the upper tails of this distribution to the extent that
21 reported food choices or diets are associated with higher exposure.

1 On the aspect of the residues, the second aspect I talked about
2 more specifically. Since residue values are anew at random, for each
3 day during the time frame of two occurring on subsequent days, may
4 not be accurately reflected understate potential at the upper times. If
5 an individual exposure is associated with pesticide residue, two
6 examples, one might be juice you drink from this morning, may very
7 well be the very same one you drink from tomorrow morning. And it
8 will have the exact same residue concentration. In
9 DEEM(FCID)/Calendex, a brand new residue was selected for that
10 second day.

11 Similar situation is bags of produce. The produce I eat today
12 may very well be from the same bag I eat tomorrow. They likely share
13 the same treatment history.

14 If the rolling time frame average in DEEM is selected, it allows
15 -- the example I gave was 7 days. But it allows the user to choose
16 various time frames. We've redone the analysis using a 7-, a 14-, and
17 21-day time frames. And you'll see these in the next graphs.

18 Increases, two things you'll note as you go through these. And,
19 again, you'll note when the next graphs are shown. But increases in
20 time frame, going from 1 to 7 to 14 to 21 over which the averaging is
21 performed, results in two main things. One is the attenuation of

1 variability; and this other is an increase in the MOE, essentially, a
2 decrease in the exposure.

3 You'll see that in the next two slides. Keep in mind that it's a
4 reverse log scale. And, also, the degree to which these changes occur
5 are dependent upon the selected percentile. The effect seems to be
6 greater at higher and more pronounced at higher percentiles than at
7 lower percentile.

8 These are shown in this slide here. The very top one, the sky
9 blue one, is the one day. What we did in the assessment using the one
10 day time period. The next three underneath that are 7-, 14-, and
11 21-day time periods.

12 So, again. These are averaging exposures. You note the
13 attenuation goes down as you go from the one day here, the sky blue
14 down here, less variability. And the there's a decrease in the MOE.
15 You're averaging additional days into it, so there's an increase in the
16 MOE, a decrease in the exposures.

17 This is actually -- this is an example of this higher percentile
18 example where the effects were more pronounced. At the lower
19 percentile example, you can see the same thing except the effects are
20 less pronounced. Again, the sky blue is the one day; and it looks like
21 the 7, 14, and 21 are almost coinciding, but they're very close.

1 I guess a series of questions would be the next set.

2 DR. KENDALL: Think I'd like you to have you stop there
3 because we'd like to have some clarification from the Panel. Then we
4 will take a break and come back with the public comment period.
5 After that, I'll have you read the questions. And then we'll begin the
6 deliberations.

7 At this point, any clarification questions from the panel? Dr.
8 Durkin.

9 DR. DURKIN: I have three quick things and it may be a lack of
10 understanding here. You indicated that Calendex makes assumptions
11 about when the chemical is applied. So if the label said it's applied in
12 the spring, that enters into it in some way.

13 MR. MILLER: That is entered into it in the residential side of
14 the assessment.

15 DR. DURKIN: Only the residential. Okay. That's fine. We'll
16 move on.

17 You showed some 3D graphs. If we asked for a 3D graph of the
18 day of the year, the percentile, and then on Z axis the chemical, would
19 that be possible? Can you spit those out?

20 MR. MILLER: If you were looking at a specific chemical.

21 DR. DURKIN: No. An array of different chemicals. It gets

1 back to my previous question about can we track these by chemical. I
2 guess that's what I'm trying to nail down real clearly here. It seems
3 like you could do it from the food, the Calendex.

4 DR. SMITH: We think we can do that. It would be a lot
5 manual.

6 DR. DURKIN: So it's not easily done.

7 DR. SMITH: It would require kind of a multi-step process.

8 DR. DURKIN: It wouldn't just spit it out. Okay.

9 And then the last item is really just a follow-up on a question
10 that Natalie had. In any of these residues is home grown vegetation
11 considered?

12 DR. SMITH: No.

13 DR. DURKIN: Okay. Thank you.

14 DR. KENDALL: Any further questions?

15 DR. RHOMBERG: On the residential exposure component, I
16 assume, does that take into account some kind of attenuation of
17 exposures over time in ways that are modeled according to residential?

18 MR. MILLER: Yes. Jeff Evans will be talking about that later
19 today. But it does. If you applied that three days ago, it would
20 attenuate that over the three day up to today.

21 DR. RHOMBERG: You made a big point of saying they were

1 not real numbers for the rolling average. Was any of this real at any
2 place? In that when these last graphs that you showed with the rolling
3 averages, were those based actually on doing the exercise that you had
4 described earlier?

5 MR. MILLER: Yes, yes. The point I wanted to make on the
6 real numbers is that, when I was showing the average, the rolling time
7 average, the Excel graphs from 0 to .014. Those real numbers there.
8 We didn't go back and look at Individual -- that's good. We didn't go
9 back. We didn't go back and look at Individual No. 1,492 plot out his
10 exposures for example. There was some confusion about that at the
11 technical briefing.

12 DR. RHOMBERG: Okay.

13 DR. MILLER: So I wanted to make it clear.

14 DR. RHOMBERG: And since you only have two days of diet for
15 each person, you are sort of flipping back --

16 MR. MILLER: Flipping back and forth, yes, over those seven
17 days.

18 DR. RHOMBERG: Randomly, you could pick the same diet
19 twice in row if it happened.

20 MR. MILLER: Yes.

21 DR. RHOMBERG: And when you come up with different

1 values, that's because --

2 MR. MILLER: Different residues.

3 DR. RHOMBERG: -- of different residues.

4 MR. MILLER: Yes.

5 DR. RHOMBERG: Okay. Thank you.

6 DR. KENDALL: Further questions? Dr. Portier.

7 DR. PORTIER: In essence on the flipping diet issue, you
8 actually flipped the diets for 365 days for an individual, don't you,
9 because the 1 to 7 is the same individual for 2 to 6.

10 MR. MILLER: Yes.

11 DR. PORTIER: And then you and 2 to 7 and then you add the
12 8. So the diet is flipped completely.

13 MR. MILLER: Yeah. But it's always connected to the same
14 individual.

15 DR. PORTIER: Just so I'm really comfortable, I want you to
16 reassure me again that the graphs that you show with the rolling time
17 frames approach, the examples are clearly not OPs since those numbers
18 are only 10 away from the BMD. Not the later graphs, but the early
19 single rolling time frame graphs.

20 MR. MILLER: Yes, yes.

21 DR. PORTIER: I want to be certain.

1 MR. MILLER: Yes. Those are not.

2 DR. PORTIER: The couple of questions I had about some of
3 the statements you made in -- 1, 2, 3 further graphs down from that
4 one -- you have pros and cons for rolling-average-based estimates.
5 There.

6 The second point. Why? I'm not sure I understand this.
7 Clearly, the assumptions that go into the analysis are violated; there's
8 absolutely no doubt about that. The double diet back and forth is
9 clearly not a realistic diet. The residues selected independently from
10 day-to-day without any correlation structure is clearly going to be
11 violated especially into details of the distribution. Why do you believe
12 this is more likely?

13 MR. MILLER: Which specific slide and which specific point?

14 DR. PORTIER: It's this slide, Point No. 2.

15 MR. MILLER: Okay. Why do we believe it's likely to provide a
16 more realistic estimate of exposures across multiple days?

17 DR. PORTIER: Yes.

18 MR. MILLER: If you're interested in a multiple-day time frame,
19 we believe that it provides -- the alternative, the one-day time frame --
20 let me take a look.

21 DR. PERFETTI: Dr. Portier, in my own simple way. The way I

1 look at it is, if you do this day by day, you're picking an individual,
2 say, at the 99.9th percentile one day and you're picking that individual
3 at that percentile is unlikely to be at that percentile on a following
4 day. Whereas for this day by day, you got a different individual each
5 time.

6 I mean if you get exceptionally bad day on one day, the chances
7 that you're going to have an exceptionally bad day for the next seven
8 days are rather low.

9 DR. PORTIER: But the question here, I guess, I'm interpreting
10 maybe differently than what you're saying. I'm thinking about
11 distributions. So I got a distribution for single-day exposures. And
12 then there's a distribution for multiple-day exposure. And the way I
13 read this is that you're arguing that the distribution seen here for this
14 procedure is more likely to be correct if you're interested in truly
15 multiple days --

16 MR. MILLER: It's multiple days, yes.

17 DR. PORTIER: -- than is the distribution for single exposures.
18 And I'm not convinced of that. I was trying to give you an opportunity
19 to convince me that the two assumptions that are violated don't simply
20 drive us regression to the mean, which is why we might see reduced
21 variability, why we'd see lower tail behavior, and to get some question

1 -- have you done alternatives? There are some obvious alternatives.
2 Don't use the two days back and forth. Choose random days and bring
3 them together, find some correlation structure from day-to-day
4 sampling, and use that.

5 Have you done any of that, some of the things we discussed
6 when Calendex came up?

7 MR. MILLER: Yeah. We've talked about that one. One
8 possibility is to hold the day constant -- hold the diet constant
9 throughout the seven days, don't randomly bounce back and forth.
10 Another possibility would be to choose different residues -- keep the
11 same residues, for example, and find out how much of an effect that
12 has.

13 We haven't gone ahead and done any of those analyses at this
14 point. We're looking for recommendations and thoughts from you on
15 how that might be applied.

16 DR. PORTIER: And let's see if I had any other questions.
17 Yeah. Two more slides down I'm trying to understand this conclusion
18 as well. Could you repeat the explanation for me.

19 MR. MILLER: Any I'll just read the slide first and then go
20 through it. Any consecutive day period of interest for an individual
21 will contain a series of repeated diets which tend to underestimate

1 variability. So, for example, if we're repeating, if an individual has
2 reported --

3 DR. PORTIER: That I got. It's the next one.

4 MR. MILLER: Okay. This will tend to overstate potential
5 exposure at the upper tails of the distribution to the extent that
6 reported diets are associated with higher exposure. So for example, if
7 I consumed, for example, two ginkgo fruits over these two days -- and
8 that's an unusual event -- I'm going to repeat consuming those ginkgo
9 fruits through all seven days.

10 So it's kind of -- in reality over seven days, I wouldn't be eating
11 those on all seven days. But it's artificially repeating that
12 consumption pattern over the seven days.

13 So if to the extent that the diet is responsible for high residues,
14 the choice of the diet, the food choices, that would have a tendency to
15 overstate the potential exposures.

16 DR. PORTIER: Okay. I guess I understand that point now.
17 And by overstate, you mean overstate to some true distribution that
18 we really don't know.

19 MR. MILLER: Yes, yes. And that's just at the higher
20 percentiles. It would be kind of a regression to the means. As you
21 add more variety to the diets -- instead of repeating the two diets over

1 and over again, if you're high, you would tend to move lower.

2 DR. PORTIER: And in the food consumption survey, were all
3 diets two days?

4 MR. MILLER: All the diets -- okay. There were -- they asked
5 everybody for two days and the data that we use in DEEM is only
6 those individuals that reported the full two-days worth of
7 consumption.

8 DR. PORTIER: So the individual-day diets are derived from the
9 two-day diets absolutely guaranteed.

10 MR. MILLER: Yes.

11 DR. PORTIER: Thanks.

12 DR. KENDALL: Any further points of clarification? Mr.
13 Miller, I thank you for an excellent presentation. We'll break at this
14 point for 15 minutes. We will reconvene for the public comments.
15 And then we will move into the panel discussion. Thank you.

16 [Break.]

17 DR. KENDALL: If everyone with take their seats, we'll
18 reconvene. Okay, this are reconvene. We're in the public comment
19 period now. We have had two individuals registered to speak. The
20 first I would like invite to the table Ms. Ingrid Kelly of Bayer
21 Corporation. If you would approach the public commentor position

1 over there. The microphone is available. Please state your name and
2 affiliation for the record.

3 DR. KELLEY: I'm Ingrid Kelley, Bayer Corporation.

4 I'm here today on behalf of the Implementation Working Group
5 to talk a little bit about their comments on the OP cumulative risk
6 assessment, especially the food exposure part of it.

7 First of all, IWG commends the Agency for doing such a
8 wonderful job in their move forward toward producing a cumulative
9 risk assessment, which is, as you all know, a tremendous job. The
10 IWG recognizes the difficulties involved and we want to be sure to
11 acknowledge that we believe that the Agency is on the right track.
12 There are many, many improvements that can be made that we can see,
13 and we would like to advance some of them here.

14 We feel that, as I said, we are on the right track. But the
15 OP-CRA process and methodology is precedent-setting technology and
16 methodology all of the other chemicals will be evaluated with a similar
17 technology. That's why we feel, as Marsha Mulkey put it, it we need
18 to put in the best and sound science. Science must be the basis for this
19 risk assessment.

20 Transparency and understanding are equally important. Because
21 if we don't have that, we don't really understand the science.

1 Stakeholder input is equally important because each of us have
2 our own little niche and we must be sure to listen to all the opinions
3 and stakeholders, including the growers who have a particular interest
4 in this risk assessment.

5 So we hope and, therefore, that the Agency will continue to
6 improve this assessment; and, finally, will give us another opportunity
7 to comment. In other words, we are hoping the Agency will produce
8 an interim cumulative risk assessment where we will have the
9 opportunity to see what the improvements might have done and how
10 further we can improve this assessment.

11 I have to put my glasses on. IWG believes that the accuracy and
12 realistic assumptions for the dietary data inputs are extremely
13 important in the cumulative risk assessment, as well as single risk
14 assessments. The assessment is, if it is peppered with overly
15 conservative assumptions, often is taken as protective would then
16 would mask the real risk drivers. Therefore, we have to be sure and
17 not be overly conservative in our assessments then we want to find
18 real risk drivers.

19 I have, myself, found this to be the case with individual
20 assessments. I have some proof of this that conservatism can, in fact,
21 lead you to the wrong direction.

1 And with this in mind, we hope that the Agency, as they have
2 indicated, will further refine the risk assessment. We hope that they
3 will consider the following considerations. Perhaps they might
4 reevaluate the blended and nonblended issues.

5 Part of the reason for that is because the new DEEM(FCID)
6 does include new recipes, new food groups, that have never been there
7 before. They should be evaluated whether or not an item is blended or
8 nonblended. This makes a big difference in the risk assessment.

9 Processing information is plentiful. The Agency has at its
10 disposal the processing information from industry; it has, also, at least
11 40 years literature around the world that has been produced by
12 scientists in universities that show that OPs, especially, degrade when
13 they are processed in homes by cooking and baking and other
14 processing.

15 We are applauding the Agency for using registered and
16 supported users only in the risk assessment. These are, after all, the
17 only thing that the Agency or industry can do anything about. All of
18 rest of it that might be illegal use should fall into a separate category.

19 We believe that the Agency should adjust the PDP data to
20 reflect only current use patterns. In the lease 10 years, many
21 companies, including my own, have come up with different and

1 competitive chemicals to OPs. These have already replaced many OPs.
2 And the 1994-1995 PDP data does not reflect this. I, again, have from
3 my own company several instances where this is the case. I will
4 forward those to the Agency, and they may share them with you as
5 they wish.

6 Also, there is the OP market basket survey which was conducted
7 on I believe 10 or 13 -- I'm not entirely sure -- commodities on single
8 servings. This data is in the hands of the Agency. They have
9 evaluated it, and we believe that it could be used appropriately.

10 We believe that the incremental changes taken collectively will
11 improve the overall credibility of the OP-CRA. We also believe that in
12 refining the assessment, the Agency will have a better tool for more
13 reliable decision-making.

14 The stakeholders need to have opportunity and access to the
15 EPA's CRA tools and data. As I have mentioned, the Agency has used
16 the new DEEM-Calendex. None of our colleagues in our industry have
17 access to this data base or this model. We have not had a chance to
18 evaluate it. The versions that are out now have not been peer
19 reviewed, even though older versions have been.

20 The new translations of recipes incorporate new food forms that
21 include baby food. We are not familiar with those food forms. We

1 have not really had a chance to get an input on that.

2 Also, these new translations -- and I don't understand how --
3 and this is where, perhaps, transparency gets lots. The new
4 translations in some way incorporate into the new recipes processing
5 factors, I was informed; and this is something where we need some
6 clarification. Because whatever processing factors we might give the
7 agency, they may not be able to use but we won't know why. So we need
8 to have some review state to find out what went on there.

9 Also, new PDP data have been used. We congratulate the
10 Agency for working with USDA so closely to obtain this newest data.
11 We are very glad for that. But the registrants and the stakeholders
12 have not had a chance to see the data as yet. It just came out, I
13 believe, last week publicly.

14 We, also, believe that it is useful, and the Agency did indicate,
15 which we're glad for, that they will do analyses using the CARES and
16 other software. We believe that is essential. Sometimes the different
17 model will point out different problems in data sets or things that are
18 important that have not shown up in one particular model because they
19 have not been anticipated.

20 Finally, the IWG supports the rolling time frame average for the
21 dietary CRA and the whole risk assessment. Partially, if the Agency is

1 going to use the BMD10 based on a 21-day toxicology value, it kind of
2 would match the hazard, the acetacholinesterase inhibition at steady
3 state with the duration of exposure. We believe that this makes sense.

4 Also, Jeff Driver will later on, for the nondietary portion,
5 inform you why there is also good reason why this makes sense for
6 nondietary considerations.

7 UDSA Food Survey Research Group should be consulted on
8 related food consumption issues as you have discussed when David
9 gave his talk. There is, for the food consumption, only one- and
10 two-day period for each individual that information was gathered.
11 And it was not in consecutive days.

12 However, the UDSA, have older data bases that do is
13 consecutive information. And this could be used to correlate
14 consumption patterns. And in addition to that, ENHANES (ph) might
15 be able to relate some of these food consumption patterns and see
16 what is the best way to handle this particular data.

17 Our final recommendations from the IWG is that EPA should
18 reissue or issue a revised or interim OP-CRA that has inaccuracies and
19 improvements included in it. Hopefully, by then, there might be a
20 comparison also and an analysis of the outcomes of alternative models,
21 the Calendex and CARES and the Lifeline. I think we can learn from

1 all of them.

2 We have to, also, evaluate the alternatives in methodologies as
3 David has pointed out. I think the Agency is doing a good job in doing
4 that. And I think they're going to go further on that. We appreciate
5 it.

6 And, finally, we do hope and we do encourage the Agency to
7 allow sufficient time for additional peer review and public comment
8 before finalizing the OP-CRA. It is an important tool for now and for
9 the future. Thank you.

10 DR. KENDALL: Thank you. Any questions from the Panel for
11 Ms. Kelly. Thank you very much. The next public presenter that's
12 registered is Dr. Judith Schreiber, New York State Office of the
13 Attorney General.

14 DR. SCHREIBER: Good morning. My name is Judith
15 Schreiber. I'm a research toxicologist in the Office of the Attorney
16 General of New York State and a Senior Public Health Official there.

17 I have a number of comments, mostly clarifications, of what was
18 discussed this morning. I didn't bring any prepared comments with me
19 today. These are all really just questions of clarification. But my
20 office will be submitted comments, written comments, to the docket.

21 We certainly thank the EPA and SAP for undertaking such a

1 broad and comprehensive and very needed assessment on OPs.

2 That said, the hotel actually provided me with this apple as prop
3 which was very nice. Just one comment regarding the ginkgo fruits
4 and how many times you might eat them in a row. I would just point
5 out it's much more likely that a family is going to buy a bag of apples
6 and eat those apples over the course of a week, perhaps one time a
7 day.

8 That's not an unreasonable assumption. I just wanted to point
9 that out. My family eats a lot of apples. And I think children in
10 general eat a lot of apples and apple products.

11 I was very concerned about the decision by the EPA of not
12 including violative and nonregistered use residues in the exposure
13 assessment. Of course, what goes into that model is very key about
14 what kind of numbers you generate coming out.

15 I was interested in whether the EPA has conducted or whether
16 the SAP had requested the EPA to conduct a sensitivity analysis of,
17 for example, using those violative residue data and looking at how the
18 assessment would differ. I think that's really very critical.

19 I don't know. Maybe someone on the SAP can inform me
20 whether that was something that was requested or has EPA ever
21 looked at that? Anybody?

1 MS. MULKEY: Why don't we hear all the questions, and we'll
2 try to address them just as we have tried with other public
3 commentators.

4 DR. KENDALL: Very well. We'll try to summarize a response
5 at the conclusion of your presentation.

6 DR. SCHREIBER: All right. I'd just like to emphasize that it
7 seems to me would be just like having a high school student grade
8 point average that we decide not to include his flunking grades, his
9 failing scores, because he wasn't supposed to fail and so we're only
10 going to include the passing scores to figure out these averages.

11 It just doesn't seem to make sense to me to exclude what we
12 know as, we do have a lot of data, that indicate that there are residues
13 on foods for which there is no tolerance for various OPs. Why not
14 include those if in fact they turn up time and time again.

15 I had asked this question once before at one of the KARAT
16 meetings, and I was told that the data is so robust, that it wouldn't
17 make any difference. Well, if that's true, I'd like to see that analysis.
18 I think it would be very important for both U.S. and imported products
19 for those.

20 One thing that I'm not sure this is the appropriate time for it.
21 But the MOEs have come up quite a bit through this morning's

1 discussion. Has the EPA or the SAP considered what is the
2 appropriate margin of exposure for the cumulative risk assessment?
3 And I understand, at least in part from this morning's discussion, that
4 that is something that EPA is not ready to decide at this point.

5 If that's true, I think the risk assessment is missing the punch
6 line, is missing the risk management part. And I think it would be very
7 hard for public commentors to make any final determination on this
8 risk assessment without that component. So I think that really is very
9 necessary and perhaps either the EPA or the SAP can elaborate on
10 what is the margin of exposure that is going to be considered to be
11 sufficient under the FQPA for cumulative risks for OPs.

12 In following the previous commentor, I, also, do agree that if
13 there is going to be substantial changes or elaborations of these kinds
14 of points in the final risk assessment, that you public be allowed to
15 comment once move before the document is finalized.

16 And one other point. I believe it was mentioned that the
17 children age one to two are the most highly exposed population. And I
18 was wondering, also, whether for the younger children from zero to
19 one year olds is exposure through breast milk and contaminated
20 formula included in the assessment in the OPs? Perhaps somebody
21 could address that.

1 That concludes my informal comments. And as I mentioned, we
2 will be providing written comments to the EPA on this document.
3 Thank you very much.

4 DR. KENDALL: Thank you. Ms. Mulkey.

5 MS. MULKEY: This might be as good a time as any to say a
6 little bit more about the violative and also talk about the canceled and
7 phased-out products. And then I'll ask our scientists. We have had
8 this question about breast milk and the water in formula and so forth.
9 So I'll ask them to go ahead and do that, and that will wrap this piece
10 up if that makes sense to you guys.

11 DR. KENDALL: Yes.

12 MS. MULKEY: Since it is the same topic that we're in the
13 middle of anyway.

14 DR. KENDALL: Absolutely.

15 MS. MULKEY: I explained a little bit of the policy thinking
16 behind the way we have addressed violations in other context. But
17 with regard to this particular data set where you have in the PDP data
18 residue levels that are above the tolerance, I understand that Dr.
19 Miller did give some data this morning about the frequency and the
20 extent of those data in the data set.

21 And I think that is a situation which we've been very mindful of

1 trying to understand the science implications of that policy choice.
2 And I don't want to leave the impression that we are uninterested in
3 that. That is why we developed the information about the extent to
4 which we're seeing it and so forth. So I don't think I have anything
5 more to say about that other than that's what led to our having the
6 information we offered earlier about the extent of that situation.

7 The other is something that also came up in public comment
8 yesterday and the Dr. Portier asked us to speak to which is the
9 chemical crop combinations. In some cases, it's whole chemicals; in
10 some cases it's chemicals and some uses as to which we have taken
11 regulatory action as part of the individual chemical risk assessment
12 process and/or where the companies have voluntarily changed their
13 registrations materially whether for risk-regarded reasons or
14 otherwise.

15 And we do have -- we have done that with regard to a number of
16 OPs and their uses. And in most cases, as is typical for a practical way
17 of ending a use, there is some kind of time line. Even when there is a
18 immediate cessation of the sale of the product, there is a period of
19 clearing the channels of commerce. Even after there is a period
20 beyond which there is now allowed use, there is a period for treated
21 foods, for example, to clear the channels of commerce.

1 So we are in the glide path for a fair amount of risk reduction.

2 I've looked at the dates, and it would take a while to read all the dates.

3 But sort of the last dates in the list are not, at this point, five more
4 years from now. Most of them end the at the end of '02 or '03. There
5 are some residential uses that go into -- there's one that goes to the
6 end of '05. But even that, of course, is less than four years from now.

7 Our thinking on this was simply that the risk management
8 choices had been made and that they were on a path of either such
9 expedition as that you couldn't practically make a lot of difference in
10 that or reasonable expedition; and that since risk assessments are
11 conducted among other reasons for the purpose of risk management,
12 that including these in the risk assessment would not materially
13 improve our risk management decision-making. So that's the thinking
14 behind that.

15 Almost all of the direct food uses have end sale dates or end use
16 dates by the end of this year, especially those on fruits and vegetable.
17 A few go into '03. That gives you a general answer. That information
18 is all available on our web site, but I won't read through each one. If
19 there is interest in a particular one, of course, we could speak to it.

20 And now maybe Dr. Smith can address the formula and breast
21 milk issues.

1 DR. SMITH: With respect to children less than a year old, or
2 for that matter any of them, the potential for contamination of formula
3 is covered to the extent that the survey would adequately reflect what
4 they ate.

5 What is not in the survey is beast milk, the mother's breast milk.
6 It is our best judgment that that is not a significant oversight on our
7 part. The evidence that we see indicates that there's not much
8 potential of OPs in mammalian milk. We are including cow's milk, of
9 course. And there are no OP residues accumulating in those.

10 So, basically, that's all I would say on that. It's not included,
11 but it's our opinion that that is not a major oversight.

12 DR. KENDALL: Any points the Panel wishes to make or ask
13 EPA? Dr. Bull.

14 DR. BULL: I have a little bit of concern, and I'm going to ask
15 this question kind of publicly. The issues related to the cumulative
16 risk assessment and there's issues that go to OP's regulatory mandate.
17 I'm trying to figure out, if we're really, truly interested in cumulative
18 risk assessment, where you would have to bring in some of these other
19 less frequent contributors to OPP exposure but recognize at the same
20 time if you do bring those in you have to realize that you can't address
21 many of those extreme exposure through your regulatory mandate. It

1 probably goes to other places within the Agency or perhaps, or
2 probably in a lot of cases, to other agencies.

3 So I'm trying to figure out when we're talking about a
4 cumulative risk assessment, are we really talking about a cumulative
5 risk assessment or are we just talking about a cumulative risk
6 assessment that deals with what's in OPP purview?

7 MS. MULKEY: We are not limited to what is within our
8 purview. I didn't mean to leave that impression. We do not, in the OP
9 risk assessment, other than some drinking-water-related
10 considerations, most of the exposure sources do happen to be within
11 our program. But I didn't mean to leave the impression that that was
12 an inherent element of our approach.

13 DR. KENDALL: Any other points from the Panel? Are there
14 any other persons who would like approach the Panel for public
15 comment? With none, we will close the public comment period.

16 I would like now to have Dr. Smith and Miller to go ahead and
17 present the questions to the SAP, and we'll move forward.

18 DR. SMITH: Question one for food. In the preliminary OP
19 cumulative risk assessment OPP used all available PDP monitoring
20 data generated since 1994 as the basis for the residue distributions of
21 pesticides in treated foods. As a result, some foods multiple years of

1 data (as many as five), while others have only a single year of data.
2 All years of data were included to provide the most robust data set
3 possible. These data were extended to cover foods and processed
4 forms of foods for which data are not directly available. Additionally,
5 some other foods were included in the analysis based on other less
6 robust data from FDA.

7 OPP is conducting a sensitivity analysis in which the residue
8 contributions from specific foods, either one at a time or in
9 combination with other foods, are removed from the analysis. This
10 analysis is being conducted as part of the effort to determine the
11 contributions of specific commodities and chemicals to the upper tail
12 of the exposure distribution. And some of the preliminary results are
13 shown in Table 1 of the addendum which was supplied to the Panel.

14 Partly as a result of this exercise, OPP has observed -- can I just
15 toss in, too -- that, also, it was shown on the slides in my presentation
16 in a slightly different forms for the sake of other people here.

17 Partly as a result of this exercise, OPP has observed that the
18 more variables, that is, commodities, chemicals, years of data, that are
19 included in the exposure distribution, the more difficult it becomes to
20 effect the tail of the distribution by removing commodity pesticide
21 combinations from the calculations. While removal most exposure

1 contributors results in a demonstrated change in the lower portion of
2 the distribution, the exposures at the upper end of the tail, for
3 example, the 99.9th percentile, are relatively unaffected by removal of
4 a single commodity even if it is identified by DEEM as a frequent
5 contributor to the high end of the exposure distribution.

6 And so we would like the Panel to please discuss the
7 significance of this observation and its potential impact on the
8 interpretation of the output distributions and the results from highly
9 complex distributional analyses such as the Preliminary OP Cumulative
10 Risk Assessment.

11 DR. KENDALL: Okay. At this point, Dr. Heeringa, would you
12 lead off please?

13 DR. HEERINGA: I'll take a first crack at this one and my
14 colleagues can join. First of all, I want to say that simulation tests of
15 the types reported in addendum Table 1 and also shown in summary
16 form in the presentation this morning, they're very important to
17 confirm that the model is performing as we expect. And I think that as
18 we get down to the development of these models and comparison, that
19 these types of simulations play a very, very important role in the work
20 that we're doing.

21 The simulation tests that produce illogical or unstable results or

1 seemingly illogical results. I believe that DEEM-Calendex should
2 provide the ability to tag and replay the inputs for these simulations.
3 So, in fact, you do have data, as I understanding Calendex, to go back
4 and analyze the contributors to these upper percentiles.

5 So in some ways, I think there's a general problem here of
6 distributional theory and a more specific problem of what happened in
7 your particular simulation; and, hopefully, we can make those two
8 consistent with one another.

9 Just a little bit on the distributional piece here. I don't want to
10 bore individuals. But in a sense when we create these composite
11 residues in a daily diet, we're compounding multiple distributions.
12 And this yields a very complex composite distribution for daily
13 residues intake. And this is a function of a number of factors. I'll just
14 list those here because they may be explanatory in what's happening to
15 you in this particular simulation.

16 We have to factor in the child's weight in kilograms, and this
17 could be highly variable for children ages one through two because
18 you're actually sampling people, children from the infants from the
19 CSFII, and taking their weight in kilograms. So that divisor itself
20 could have a factor of twofold.

21 And I'm not sure, given how diets are reported for these

1 children, I mean you put an apple on a high chair tray and about half of
2 it goes to the wall and half of it goes someplace else and a quarter of it
3 may go down the stomach. So those issues I think are there. I don't
4 think that's going to be the answer, though.

5 The diet for the day, obviously, is very important in determining
6 these distributions of total residue intakes. First of all, does the food
7 appear in the diet? And there are any number of foods that could be
8 considered. It's a narrower set for one to two year olds.

9 Secondly, if the food appears, is there a positive residue amount
10 assigned to that food in the stochastic draw. If I recall correctly from
11 previous reviews of these DEEM models and others, that in many of
12 these foods, there's a high proportion that come from untreated or
13 presumably zero or no detect residues. So even if the food appears,
14 when we that the stochastic draw for the day of the residue amount,
15 we may get a zero value for it. So there's a tremendous amount of
16 variability.

17 And then for non-zero amounts, it's actually the value of the
18 stochastic draw that does take place. If we think about the
19 distribution, the means of the these distributions, essentially, because
20 we're treating these foods independently, the means are essentially the
21 sum of the individual expected values for all the contributing

1 distributions.

2 In other words, you have a distribution for every food
3 component that could appear in that diet for the day. Obviously, the
4 only ones that come into play in any significant way are the ones that
5 are consumed during the day.

6 The mean of that composite for the day is going to be the sum of
7 the means for the individual components that go into it. Likewise,
8 since we assume independence in our draws of these residue amounts
9 for the foods, the variance of that composite distribution is also going
10 to be the sum of the variances of the individual, non-zero food
11 contributions from each source.

12 Removing food groups A, B, and C, as you've done in the
13 simulation, changes the mean and the variance of this composite
14 distribution. And, in fact, as I looked at this, my first response to
15 your question is I don't see the problem here because it looked to me
16 that the results from your simulation appear to be very consistent with
17 what we expect, not just the removal of groups A, B, and C, A but
18 even the sequential removal of A and then B and then C appear to
19 produce a logical shift in the distribution of this residue distribution.

20 So the changes that you observed, and you actually
21 acknowledge in terms of the form of the distribution rate, are exactly

1 what we would expect. So I didn't see anything unusual there.

2 The importance of foods groups A, B, and C to the composite
3 distribution is quite obvious. You get a three-and-a-half fold decrease
4 of mean MOE; a fourfold decrease in the 95th percentile. So, clearly,
5 removing these groups is dragging the body of the distribution back
6 toward the origin here.

7 Now, a 2.5 decrease in the 95th percentile, which I think is
8 significant in many ways. And even a two-fold decrease in the 99.5th.
9 But focusing on this 99 and 99.5th, which is your problem, the
10 distribution of these quantities in this composite distribution is really
11 somewhat unrelated to the distribution of the composite itself.

12 In other words, we can do a lot of things to the body of the
13 distribution without being able to influence this extreme tail and really
14 a function of the extreme values generated under of -- and not so much
15 the function of the mean and particular variance of the composite
16 distribution.

17 If you think about it, if I were to analyze the DEEM inputs to
18 the particular simulation, if you think about how foods A, B, and C
19 can contribute to extreme values, there's really two ways. One of
20 them, is A, B, and C can form a stepladder. They are big. They are
21 prevalent in the diet. They may have large residues. So they serve as

1 a stepladder.

2 And then we come along and we get another extreme value on a
3 less commonly consumed food and added to that A, B, C value, it puts
4 us into the extremes. So essentially, A, B, and C are boosting some
5 other not so extreme values from other into the extreme.

6 The other way you can get it is that A, B, and C could actually
7 be generating the extreme values themselves. And i think the basis of
8 your question, you're sort of assuming, well, I removed A, B, and C,
9 so A, B, and Cs extreme values aren't there. So why aren't the extreme
10 values changing in the distribution.

11 Well, the only thing that you really removed is you removed the
12 ability for A, B, and C to boost something else up or for A, B, and C
13 to generate its own. Now the probability that A, B, and C in a mixture
14 of diets is going to generate those extreme values all on their own is
15 relatively small because there are only three groups. And if you think
16 about it, even if the entire residue distribution were based on A to get
17 to the 99.5th percentile, you essentially have to something with odds
18 of almost 99.9th percentile, you have to have something that has odds
19 of one in a thousand of being drawn from a distribution.

20 So the probability of getting an extreme event from A, B, and
21 Cs residue distributions extremely small; and even in combination, it's

1 pretty small. So what happens here is that you've got 69 other food
2 groups which might occur someplace in some child's diet during your
3 simulation run and each of those 69 food groups also has extremes,
4 and so as I sum across all of these children in the particular profile for
5 a given day, someone is going to eat these odd foods.

6 And although they aren't as prevalent in the diets as A, B, and
7 C, the sheer numbers of them that could be there and the fact that they
8 could each contribute with some low probability an extreme value,
9 essentially the strength in numbers means that you're still generating
10 extreme values from all of these low prevalence food groups; and so
11 these maximums are not being affected as much as you might think.

12 That's my statistical explanation. In other words, you have
13 several different routes. And that what's happening is because you are
14 still generating potentially with low probabilities but add small
15 probabilities across large numbers of food groups, you generate higher
16 probabilities for generating extreme values from these sort of
17 nonprevelant foods.

18 I suspect that that's what's happening. This is a guess. And
19 you'll be able to affirm that with DEEM. We can't rule out what I
20 think are more pathological explanations in a statistical sense. That
21 there may be some -- and this is what I think you're hunting for --

1 extreme residue commodity potency factor relationships in DEEM that
2 don't make sense and are producing these outliers. Clearly, you want
3 to hunt those down and try to rectify the data there to make sure that
4 it is consistent with empirical data that you have on these
5 distributions.

6 Also, another factor that occurred to me is that potentially,
7 even though -- and this is really a stretch but I think it's worth looking
8 at in your analysis. If you remove food groups A, B, and C, we're only
9 looking in the simulation at a short one year interval. But most of us
10 know that children's diets change considerably over that one year
11 interval.

12 So it could well be that what you're doing when you remove A,
13 B, and C is that you're actually removing foods that are eaten later in
14 the interval, like whole fruits and vegetables, as opposed to sort of
15 mashed fruits and vegetables or other types of cereals at the
16 beginning. There may be some time-related dependency between food
17 groups A, B, and C in the year one to year two.

18 And why would that be important? It would be important
19 because the it affects the weights of the these children. The weights
20 of these children could be actually the kilogram divisor in the exposure
21 could be changed.

1 So those are, again, the last is a bit of a stretch. But I think if I
2 had to analyze how to decompose the problem, theoretically, I think
3 what's happening is that, as you draw out A, B, and C, you are in fact
4 contracting this distribution significantly, pulling the body of the
5 distribution back toward the origin, but you're not able to impact the
6 very extremes because you still have this underlying, very thin extreme
7 value distribution for all these other components.

8 DR. KENDALL: Thank you, Dr. Heeringa. As you can hear,
9 there is music next door. We did not know this. We were only
10 informed this morning that apparently there is to be a concert in ten
11 minutes. So I'm going to -- which started even earlier. And, quite
12 frankly, apologize for this happening. We were just notified a couple
13 of hours ago. So we're going to take our lunch break beginning at
14 approximately 11:30.

15 I ask everyone to bear with us for the next ten minutes or so. I
16 hope that will work. And they'll be concluded by 1230, and we'll
17 reconvene. So let's grin and bear it. And, Dr. Reed, can you follow
18 Dr. Heeringa, please.

19 DR. REED: Yes. I just want to commend the Agency for the
20 enormous task and a lot of work put into it. It's impressive.

21 What Steve was saying, I totally agree. It's a very complex

1 analysis. I'm sure if there is an easy way to go back and see what
2 happened to it or in terms of what is the major contributing factor
3 except to do what you're doing. And that's something we do very
4 often in our program, too.

5 I think even down to look at the CC to identify the high
6 contributing commodities takes some looking around. You've looked
7 at three of them. I want to follow what Steve was saying in that,
8 actually, after you get rid of three of them or even one at a time, look
9 at the CC again and see if you're right on track.

10 Also, when you look at the CC, as Steve pointed out, see that
11 the H vector would come in to play within that 3-to-5, 1-to-2 bracket.
12 The eating pattern, the distribution of contribution from different
13 commodities, that sort of thing. A lot of times we have to go back and
14 forth and find that high contributing commodities that way.

15 I'm sure there are many more sets of sensitivity analysis that
16 could be done. Something was mentioned -- and I thought it was
17 worth sort of mentioning again -- was the curiosity of whether
18 chemicals will make a difference. You're looking at commodity;
19 contribution, look at the chemical contribution.

20 Other things are -- I mean, in that case, you sort of trap the high
21 contributing chemical and then do as you did, removing one at a time

1 and to see what happened.

2 In terms of things to consider, I think there's so many things to
3 consider. But the Agency is under the time constraint to complete
4 something at this time. What I was thinking was as the most important
5 thing is this: From the presentation and the document, it reflects a lot
6 of experience from the Agency in doing what you do and giving the
7 assumption that we assume, for example, dietary exposure does not
8 fluctuate significantly over the year, that type of thing, or even though
9 it's calendar-based in terms of the whole assessment but dietary is not.
10 You know, these assumptions, PDP data, single unit analysis data, will
11 not impact a whole lot as compared to using composite.

12 I think the Agency has lots of experience with this. It would be
13 good to present it in a way. I think people would like maybe to see
14 some support instead of just a single sentence statement. I think that
15 would help.

16 DR. KENDALL: Thank you, Dr. Reed. Dr. Zeise, would you
17 like to follow, please.

18 DR. ZEISE: I agree with the comments earlier, and I think the
19 explanation provided for the finding is very reasonable. And,
20 obviously, we need to explore to see really what is happening in the
21 tail and whether or not there is a problem with the model or whether

1 or not that explanation that was given holds up.

2 In addition to exploring that, I think it's very important to focus
3 on the tails. It represents many individuals in the population. And it's
4 important, I think, to explore other factors that might change the tail
5 significantly. It's not clear the extent to which violated exposure
6 would change that. The extent to which consideration of degradates
7 might change the assessment.

8 And then the issue -- and I didn't see it explored in the
9 document -- of binge eating and seasonality of fruits coming in in the
10 summer months, and so forth, if CSFII appropriately captured some of
11 the cases where you might expect larger exposure. I think that would
12 be useful to explore.

13 And the nondetect, I'm assuming that that has been adequately
14 addressed. There was a discussion in the document. It wasn't clear to
15 me the extent to which, if you assumed at the high end of the
16 distribution, if you threw in some nondetects as half the detection
17 level, whether or not it would significantly change the evaluation at
18 the tail.

19 And the reason why it is so important to look at the tail is that
20 the MOE is rather small there. In fact, if there are even larger
21 exposures than that, that really indicates that there is a problem. So

1 really understanding that region is important. And I'll leave it at that.

2 DR. KENDALL: Thank you very much. Any comments from
3 the Panel in addition to the comments already made on this particular
4 question?

5 DR. MCCONNELL: Yes. I was struck by the fact that you
6 depend a great deal on the UDSA for a lot of your input in your
7 calculations. I was wondering, and it was suggested by one of the
8 people from the audience, that you have relationships with UDSA. I
9 don't know what they are. Do you have periodic meetings with them
10 to update yourself with what they're doing? Their science must be
11 evolving as is your science, and do you have a way to keep up with
12 that?

13 DR. SMITH: Yes, we do. In one area, of course, one of the
14 major areas we're discussing today, are the residue data that we're
15 using. That's the PDP program. And we work very closely with them.
16 We advise them as to what our interests are and then things we'd like
17 to see done from year to year. So it's a very close relationship. Also,
18 there has been considerable interaction in the area of the CSFII. I
19 don't know that I can say much more about that; other than I don't
20 know if, David, is there anything you'd like to add to that?

21 MR. MILLER: Yeah, we do communicate with USDA on the

1 CSFII and the food research group that is responsible for it.

2 DR. DURKIN: Thank you.

3 DR. KENDALL: Any further comments? Dr. Durkin.

4 DR. DURKIN: Very briefly, we will be discussing residential
5 exposure at a later time. But this does relate to food and, again, it is
6 the issue of homegrown vegetation. I did not see that in the
7 residential exposure. And we may clarify it then. But it's clearly not
8 in your food exposure. And I'm rather concerned that that could be
9 the 800-pound gorilla.

10 The concern is with people in a rural area, especially rural
11 south, who may live in a region of agricultural usage that could be
12 very high. And I am a little concerned about what I've heard up to this
13 point that we could have, again, a bimodal distribution of risk that
14 we're simply not addressing.

15 DR. KENDALL: Okay. Any further comments? Mr. Lewis, our
16 DFO, has informed me that they're running late over there. Therefore,
17 we may have time to go to the next question. I'd like to take an hour
18 break. So could we procedure into the next question as recommended
19 by the best intelligence information I've got. And it's the military next
20 door.

21 MR. MILLER: The Calendex model can be used in a number of

1 modes to develop a profile of exposure estimates. In the current
2 assessment, OPP conducted a series of single-day assessments arrayed
3 chronologically to develop a response surface of exposures. A
4 constant percentile of exposure was selected to represent the potential
5 exposure to a given percentile of the population. For example, the
6 99th percentile for each day would be arrayed for 365 days to reflect
7 the population estimate across the calendar year.

8 Calendex can also be used in a multi-day sequential series
9 analysis, as referred to as a "rolling time frame mode." A rolling time
10 frame provides an estimate of the average of daily exposures for an
11 individual calculated over multiple (7, 14, 21, or 28) days for each
12 multiple day period over the course of a year, (e.g., days 1-7, then
13 days 2-8, then days 3-8, etc.).

14 In this model, an individual's food exposure is tracked across
15 the calendar year by randomly selecting day one or day two of that
16 individual's reported consumption from the CSFII and combining each
17 commodity which comprises that consumption with randomly selected
18 residue values for each day of the calendar year. These rolling
19 averages for each individual are assembled to develop a distribution of
20 rolling average exposures.

21 During previous SAP meetings, the Panel has expressed concern

1 about the use of CSFII records to represent longitudinal consumption
2 patterns for individuals. Concern arose as a result of the design of the
3 CSFII study, in which two nonconsecutive days of data (separated by 3
4 to 10 days) were collected for each individual.

5 Please comment on the use of CSFII data to support each of
6 these two modes of Calendex as they pertain to the cumulative risk
7 assessment of pesticides in foods.

8 DR. KENDALL: Dr. MacDonald, can you lead off, please.

9 DR. MACDONALD: Well, I guess to begin with, I'm under the
10 impression that CSFII is about all we have that's relevant. So we don't
11 have a lot of choice here. I guess there would scope for doing some
12 kind of sensitivity analysis to see what the impact would be of having,
13 say, you could make up some data on longer term records and just see
14 what impact it would have on the estimates.

15 As far as the different modes of running the Calendex model
16 goes, I think Dr. Portier's remarks earlier were very relevant. And I
17 hope they'll get into the response for this question.

18 But, basically, I think the effect of using the rolling average is it
19 will mitigate effects of sampling nonconsecutive days to some extent;
20 but, mostly, it will just reduce the extremes in the simulation.

21 Is this relevant? I don't really know. I think we have to know

1 more about the metabolism of the OPs in humans at different life
2 stages. I think the limitation here is the margin of exposure computed
3 as the point of departure divided by exposure, so we have to make sure
4 that the exposure measure and the point of departure are both
5 relevant.

6 For example, what we saw yesterday in the adult rats, the dose
7 response curve, we saw there was a shoulder and in many cases in that
8 suggest in some situations a moderate short-term exposure is totally
9 innocuous. But that's for adult rats. As the NRDC has pointed out, it
10 might be totally different in humans; it might be totally different in
11 human infants and fetuses. So it's really hard to say what the effect of
12 changing your exposure measure is going to be if we don't really know
13 what type of exposure is most relevant in the population we're
14 considering.

15 I think to conclude, the rolling average is probably a good idea
16 if the main concern is chronic low to moderate levels of exposure. But
17 if the real concern is acute levels, than reducing the extremes is
18 perhaps going to be missing some of the more dangerous episodes.

19 DR. KENDALL: Thank you, Dr. MacDonald. Dr. Freeman.

20 DR. FREEMAN: The two methods used with Calendex, you can
21 almost think of them as bounding examples. The use of a single-day

1 constant percentile of exposure for every day provides an exceedingly
2 conservative estimate of exposure. It is clearly not representative of
3 individual exposures over time. And I find it difficult to understand
4 what it actually means in terms of population exposures. And, also,
5 I'm not quite sure how you're going to use that.

6 In contrast, the second method which uses the rolling averages,
7 is not only less conservative, but for very young children when you
8 only have two samples of food, may actually reflect what young
9 children over a limited time period, as Dr. Heeringa was suggesting, is
10 fairly realistic. Young children tend to have very narrow food habits.
11 So that while you only have two samples to draw from, they probably
12 aren't that different from each other because the children aren't eating
13 a wide range of foods. So that may actually be useful in representing
14 sort of the average young child with fairly limited ranges of foods in
15 their diets.

16 On the other hand, that same rolling average, because you only
17 have two food samples to work with, may underestimate or suppress
18 the high-end exposures from diets in the same children. And I'm not
19 sure what you can do about that.

20 A concern of mine is in the application of all this stuff. In the
21 examples that you give, you suggest that diet is treated as uniform

1 throughout the country. And unless you have already done so, I think
2 this is a hypothesis that needs to be tested, particularly in areas such
3 as Region 3, the Texas Fruitful Rim, which are predominately
4 Hispanic. I wonder whether the diet for based on the CSFII for the
5 total United States is really appropriate. And one thing that you could
6 do is to compare the diets associated with that region from one such as
7 the Easter Upperlands or the Northern Great Plains where the
8 demographics are very different.

9 Another alternative -- that also assumes that the CSFII has not
10 under represented minorities in their sampling, which may also be the
11 case. And if that's the case, you may have to go back and look at
12 census data for those areas and do some sort of proportional weighting
13 based on census characteristics.

14 So that adds more complexity to your model.

15 DR. KENDALL: Thank you very much. Dr. Reed.

16 DR. REED: I want to follow up on what Natalie was saying. I
17 think, basically, if we take a sort of a common sense way of thinking,
18 we would think that the diet has seasonality and has regional
19 differences. Again, I think it's partly I think because of the Agency's
20 experience in this area, knowing the impact of parting them out into
21 region and season, and maybe it doesn't come out to be a whole lot in

1 terms of impact. And it's time consuming and it's not readily available
2 in terms of tools right now with DEEM and Calendex. I'm not sure
3 about that part.

4 But what I'm trying to say is that I think it would be good to
5 give some support to that assumption or, as Natalie was saying, run
6 some data sets. Remember, we've in the past looked into things that
7 are important to children. For example, apples, they do have
8 seasonality and also regional differences. It could be up to about
9 20-percent differences. So it's something that probably is worth
10 looking into.

11 In terms of using that data for medical day sequential analysis,
12 you have already presented the pros and cons. But I remember -- I
13 just have one simple comment. I remember in September 2000, when
14 we look at Calendex, there was the recommendation to look into this
15 method. And I'm still very interested in following up on that.

16 That is instead -- I think maybe the overriding desirable idea
17 right now for you is to trace an individual. And, therefore, you think
18 that perhaps you need to stick with these two data points. But I think
19 there's somewhere in the document that emphasizes that you're not
20 actually tracing individual exposure pattern. So in that case, it is still
21 possible, as what we recommended before, to base on demographic

1 characteristics, to pull the data together so that you would have a
2 larger sampling size of population to draw from instead of just two
3 points.

4 And I don't know how difficult that is. But I think that's
5 something that's still worth looking into. I don't know if I'm clear on
6 that point.

7 DR. KENDALL: Is that clear?

8 MR. MILLER: Yeah. I think what you're saying is when you
9 say "pool the data," the way it's done now is each individual's diet is
10 connected to that individual.

11 DR. REED: Right.

12 MR. MILLER: Each of those two days worth of diet.

13 DR. REED: Right.

14 MR. MILLER: What you're saying is maybe draw from,
15 essentially a pool that has demographic similarity to that individual.

16 DR. REED: Right. Three to five pool with different seasons,
17 four seasons.

18 MR. MILLER: Okay.

19 DR. KENDALL: Very well. Dr. Heeringa, anything to add?

20 DR. HEERINGA: Just briefly to Dr. Reed's comments. I think
21 the idea -- right now, the way that you're using the CSFII data, is

1 essentially you're locking a child's body weight and gender and age
2 into a particular diet or maybe at most three diets if in the CSFII and
3 two diets for the infant and child observations in the '98 CSF.

4 And what we're doing there -- I don't think of us believe that
5 this child is going to eat macaroni and cheese 365 days a year. But in
6 your sample someplace else, there's a child eating green beans and a
7 hamburger or there's a child eating oatmeal. So what you do is even
8 though you're focused on an individual child, what you're assuming is
9 exchangeability among children of the same age and same gender. And
10 the thing you're doing is you're locking a particular body weight to a
11 particular diet.

12 I think that's a constraint you don't need to use. Dr. Reed's
13 suggestion is essentially sample the child. You need to get a
14 representative samples of children with their body weights and their
15 genders and their ages. But then, among children in your national
16 sample, which you're assuming to be exchangeable anyway, sample
17 their diets to link to those on a daily basis.

18 So I think that breaks one sort of false correlation in your
19 current input structure that is unnecessary and doesn't contradict in
20 any way.

21 Now, on the other response to this question, you are

1 constrained by the fact that you have two or at most three days of diet
2 for any individual. By putting things in this pool, you've sort of
3 unconstrained people's diets a little bit. But you haven't actually built
4 in realistic patterns. You still have to assume, if you go Dr. Reed's
5 route, that you have random eating and that there are no consistent
6 correlations over time in consumption patterns. Which we know for a
7 bag of oranges or a bag of apples or a bunch of bananas or even things
8 like green beans, you might be eating them two or three times during
9 the week in which they're bought. I think that's another level of
10 sophistication that you might think about bring in at least in terms of
11 simulation.

12 And this is what Dr. Portier brought out, yesterday or earlier
13 this morning, that you might look at some testing in the model where
14 you do two things. And that is you have a lag factor in the
15 consumption in the dietary intake for some of these commodities that
16 we know are going to be in the household for a protracted period of
17 time. And I don't think macaroni and cheese is going to be one of
18 them. But apples and various fruits that are bought in larger
19 quantities than vegetables, and see what that does.

20 And if you do that, then I think you, in addition to sort of
21 introducing a lag in people's dietary consumption during the period of

1 a three- or four-day average, also preserve the draws on the residue
2 amounts because it's only realistic if you do that that these
3 commodities that came from the same source would be expected to
4 have nearly similarly residues amounts. We know there will be
5 variability, but much less variability than a completely random draw.

6 So I think with the data that you have available and some
7 assumptions -- and, again, I would only put this in simulation context
8 right now, to look at what happens when you introduce not only
9 lagged consumption from one day or time-correlated consumption of
10 some of these commodities for short periods. And I would say three
11 to four days would be fine on most of these or a week. And then, also,
12 to preserve the residue amounts associated with those.

13 Now, that's complex, I know. But I think that would add a little
14 bit more reality. Now if you do that, then I think this whole issue of
15 whether you use these rolling averages or individual days, the rolling
16 averages make sense as a measure of sort of short-term chronic or
17 maybe steady state impacts of the residue consumptions; but I think
18 they only make sense if you do these other steps. And that is allow
19 foods to have time correlation over short periods of time and that the
20 residue amounts on those fruits are also preserved as draws from your
21 residue distribution. Then I think these rolling averages do approach a

1 better reflection of what the sort of chronic exposure over a 28-day
2 period is more likely to be.

3 I think if you're doing fixed diets for kids, random draws of
4 residues everyday for each child. I'm not sure that you're getting from
5 these rolling averages what you would really like. It's not a good
6 reflection, I think, of chronic exposure. And the one-day stuff gives
7 you the acute exposure in a better sense, I think.

8 DR. KENDALL: Any further comments from the Panel? Dr.
9 Portier.

10 DR. PORTIER: I agree with all the comments that have come
11 forward, starting with the one that said you guys did a great job on
12 this. But presuming something we can look at and comment on is
13 really pushing the edge of what's been done previously.

14 I was sitting here trying to think about my question earlier
15 concerning the conservativeness of this particular method. Especially,
16 the two-day flipping back and forth. And your observation that you
17 think this is going to be somewhat conservative. And we had several
18 questions about that from lots of the public yesterday, both the
19 grower's side and the environmental side asked a question to what
20 degree can we assume this is conservative.

21 So I'm sitting here trying to ask myself how do we assess that

1 without doing a full independent resampling scheme where everything
2 is independent. As Ruby pointed out, you sort of have two extremes
3 that you could do. The first extreme is the individual day data, run it
4 for 21 days. But that's exactly the same as the distribution for the
5 individual day. Taking the average of that over the 21 days is going to
6 give you exactly the same distribution. So you've got that one. That's
7 one extreme.

8 The other extreme is everything is random. Every day a new
9 draw, a new diet. Everything is completely random. That's the other
10 extreme in the sense that we know there are probably some
11 correlations in there.

12 But we know something about the other extreme. If your
13 distributions are normal, which they're not. Then I'm going to choose
14 the simplest case here. If your distributions were normal, you know
15 that by averaging over 21 days, independent normal random variables
16 drawn on a day-by-day basis, the 99.9 percentile, in fact, any
17 percentile except the 50th percentile, is going to change by a factor of
18 4.6; the square root of 221.

19 If it's log normal, you can actually calculate the same things.
20 The 99.9th percentile. But it's not a constant. The 99.9th percentile
21 change is about a factor of 12. The 95th percentile change is about a

1 factor of 6.

2 But the point there is you can look at your two-day consecutive
3 draws, compare it to your extreme single-day case, and ask yourself,
4 have I dropped the 99 percentile and the variances by some number
5 that appears to be in this range or less. So is it on the conservative
6 side or on the independent side?

7 Judging from your quick graphs there, David, it looks like it's
8 on the independent side not on the conservative side in terms of a very
9 consistent redraw. But I'm not sure because I don't see the full
10 distribution for that.

11 But I think you could address it that way. You might see some
12 mean shifts as well which could tell you something about theoretically
13 how conservative that approach might or might not be.

14 But I agree with everyone that you need to try some other
15 things, potentially theoretical or to resampling technique.

16 DR. KENDALL: Thank you. Any further comments from the
17 Panel? Dr. Rhomberg.

18 DR. RHOMBERG: Just briefly. And I hope this is the right
19 place to raise it. On the single-day analysis, you know, in the end
20 what that is able to show is seasonality. Otherwise it's just doing the
21 same thing over and over and over again and they're just replicates.

1 The only thing that's really different between one day in January and
2 another day in May is seasonal differences.

3 And I guess I was struck by the fact that there didn't seem to be
4 many, that if you looked at those graphs, including the one that's right
5 on the front of the report there. Yes, there's some variation up and
6 down; but there's no big sway, no big seasonal sway of going up and
7 down.

8 And my question is why is that? I would really have expected at
9 least some such effect. And the only reason that there wouldn't be any
10 is if seasonal effects are at all important, that they are somehow
11 excluded here. Would that mean that seasonal effects are driven
12 maybe more by seasonal effects on food choices than they are by
13 seasonal effects on residues or what? I guess I'd just like some
14 discussion of why there isn't more seasonal effect there when one
15 would expect some.

16 MR. MILLER: I'll say we're not -- when we use the PDP data,
17 we're not taking into account -- and it's just clarify it. We're not
18 considering the seasonal effects of when the food is sampled. So there
19 is no seasonal component.

20 When I said we start with January 1, it's not necessarily a diet
21 that a person reported eating on January 1. So for example, when the

1 CSFII went out, they didn't -- the January 1 diet is not specifically a
2 January is 1 diet. It was essentially the seasonality component is
3 added to the assessment by means of the drinking water which is
4 seasonal. We take into account the season there and the residential
5 uses.

6 DR. KENDALL: Any further comments? Yes, Dr. Zeise.

7 DR. ZEISE: I just want to reinforce the idea that when you
8 consider the averaging period, you carefully look at the
9 pharmacokinetics in humans and determine what makes sense to do. It
10 might make sense to actually build in a pharmacokinetic parameter to
11 address the issue of persistence across time.

12 DR. KENDALL: Very well. We understand now the program
13 next door may go as late as 1, so I'd like to try to move into 2B. We
14 are tracking their program. I think somebody is speaking at this time,
15 to be followed by a concert. The concert is going to blow us out of
16 this room. So let us push forward.

17 Today's one of those challenges. We will take a break for one
18 hour. And I will see you for 1 o'clock. Thank you very much.

19 [Lunch recess.]

20 DR. KENDALL: We'll go ahead and get started. This will
21 reconvening the SAP. The point at which we are currently is

1 addressing Question 2B. Please read that question, Mr. Miller; and
2 we'll go on from there.

3 MR. MILLER: The random PDP residue values assumes that the
4 residues in foods consumed across a series of days are independent of
5 each other. In other words, foods consumed are from unrelated
6 sources and there is no carryover from one day to another. This
7 assumption may be inappropriate given that many consumers obtain
8 food in bulk (i.e., multi-day) quantities that may have similar
9 treatment history and would typically consume this food over a short
10 multi-day period (e.g., leftovers). In such a case the residues
11 contained in the foods would violate the assumption of independence.

12 Please comment on the use of PDP data to support each of these
13 two modes of Calendex as they pertain to the cumulative risk
14 assessment of pesticides in foods. What issues are likely to accrue
15 from the assumption of independence in residue data?

16 DR. KENDALL: Dr. Reed, can you lead off, please.

17 DR. REED: In terms of single-day exposure mode, I don't have
18 a lot of problem with it. As long as it was clearly stated, you know,
19 what the announce is about. I think the only issue that we're been
20 throwing about is the composite nature of the data.

21 We knew that from single-eating-size analysis that you would

1 have essentially higher, possibility to a higher, residue in a
2 single-eating-size sample. But that's for a single chemical. And I
3 don't have any feel about what is it going to look like for index
4 equivalence-type of residue data base.

5 So I would really appreciate that, again, I think that assumption
6 was that there's not a substantial difference in it. And I think it would
7 be good to present something like that in the documents so a reader
8 could understand and follow.

9 In terms of multiple day rolling average, I think PDP data is
10 suitable for that, especially when the composite is not a problem. I'm
11 not sure -- or I am sure that this does not really address the carryover,
12 leftover, or same batch exposure scenario. I would go about and find
13 the heightened contributing commodities and see if linking days would
14 make a difference. I would not offhand go in and link everything from
15 day-to-day yet.

16 The reason I say that is because I think linking days would be
17 really specific to certain foods. You know in the past we talk about
18 Thanksgiving meal and that kind of thing, also the buying-eating
19 pattern; people buy a bag of apples and eat for how many days;
20 shopping pattern and all of that.

21 That being so, I think what I'm thinking is it's important to find

1 places where it might make a substantial difference and not just
2 shotgun and go in and do all of that. And I'm thinking of that mostly
3 in terms of resources. And I'm thinking of now of approach and risk
4 assessment is about. You decide when and why you want to go in and
5 refine something so that you're more focused and you're not spending a
6 lot of time and effort.

7 That goes back to the comment that I made earlier that it is
8 important to make a clear presentation in terms of what are the
9 assumptions and why you think so; and so when it comes to the steps
10 whether we link days or not, it would be much clearer as a choice or
11 not.

12 DR. KENDALL: Thank you. Dr. Heeringa.

13 DR. HEERINGA: I very much agree with what Ruby has just
14 presented. Just a few added comments.

15 In response to the earlier question, I mentioned exploring the
16 issue sort of continued consumption of a single food item over several
17 consecutive days. Again as Ruby has just pointed out, it requires
18 modeling, buying, and retention patterns within the household. My
19 sense is that even has something sort of three to five days retention of
20 a fruit or vegetable batch would be an appropriate bound to set on
21 testing that.

1 Clearly there if you do that, then I think you want to preserve
2 the sampled residue amount over those three to five days, also, to
3 preserve that correlation which you would naturally assume in the
4 purchased food product.

5 With regard to the independence on a single-day analysis, I
6 think the independence assumptions, since you're doing it on a daily
7 basis, it really doesn't come into play. It's more when you look at sort
8 of chronic or accumulating over multiple day analyses that I think you
9 need to take into account the correlation, not only in foods eaten, but
10 also the residues on those particular foods over the days.

11 One additional comment to, I guess, related to the question,
12 that is, the use of OPP residue data base. I believe that most of these
13 are composite amounts. We're not only compositing the servings over
14 the day, but we're also compositing the residues over multiple articles.
15 If anything, I think that would tend to attenuate the extremes that we
16 would observe on a daily analysis.

17 So if anything, it's probably a little bit anti-conservative to use
18 the composited, samples as opposed to some strategy which I know
19 we've investigated in the past to try to derive a single serving or a
20 single-serving residue amounts for use in these analysis.

21 DR. KENDALL: Dr. MacDonald. Thank you, Dr. Heeringa.

1 DR. MACDONALD: I don't have a lot to add to Dr. Reed and
2 Heeringa. But I will express my sympathy for what I see what must be
3 a very frustrating situation because there are just limitless ways to
4 start making these models more complicated and you'd really like to
5 know ahead of time which of these ways are going to be worthwhile.

6 I guess all I could suggest here is if you -- I don't think you
7 even have to do a pilot study. If you could make up some the data
8 with the consecutive days or with the correlations built into it and just
9 try some small simulations and see what kinds of differences it makes.

10 Certainly, that in the other context, the study you did with the
11 A, B, C gave some -- it seemed to be a very simple thing to do, but it
12 gave a very useful results fr what would happen if you change some of
13 the data. And maybe you could devise something like that with the
14 correlations.

15 DR. KENDALL: Dr. Zeise.

16 DR. ZEISE: I don't have a lot of add to the comments that
17 already been made. We've talked about this this morning as well.

18 The one thing I would add is that there are likely to be
19 differences across the different age groups in terms of the extent to
20 into which this comes into play. And particularly for the younger age
21 groups, one would expect a lot more similar behavior from day to day.

1 As an upper bound kind of analysis, one might assume that every day
2 they consume the same value or sample between the two days.

3 Another possibility comes to mind along the lines of -- I like the
4 idea of the correlation analyses that have been proposed. And another
5 possibility would also be to do some scenario plane to kind of test and
6 speculate what could be happening at the extreme by looking at
7 different scenarios for some high consumption of foods, say, during --
8 I don't know -- watermelon season or when you might expect very
9 large consumption of fruits more so than other part of the year among
10 certain subgroups.

11 DR. KENDALL: Good point. Any further comments from the
12 Panel on this issue in food exposure? Dr. Portier.

13 DR. PORTIER: Not specifically on this. Well, let me ask a
14 question on this one first.

15 Steve was just asking me, and I guess we're both a little
16 confused about the issue. If the PDP data set has a residue that
17 exceeds the limit, you still include that in the analysis? Yes or no, you
18 take those out?

19 DR. SMITH: We take out residues that exceed tolerances, yes.

20 DR. PORTIER: Then I think from my perspective, I would
21 recommend you not do that. I think it's going to be there's two

1 reasons. One is it's going to happen no matter what the tolerances are
2 set; there will be samples that exceed the tolerance. That's the first.

3 The discussion we had of where PDP data comes from and the
4 question of what happens when people buy things in the market or
5 from not necessarily the large commercial sources, there may or may
6 not be higher residue levels depending upon when and where, et
7 cetera, where they buy it. And those things are just unknown. My
8 recommendation would be that you include them in your over all
9 analysis. And I don't know how the rest of the Panel feels about that.

10 The other point I wanted to make, which is more general, is
11 yesterday we had a discussion about point of departure for margin of
12 exposure from the point of view of hazard. And much of our
13 discussion pertains yesterday pertains, also, here especially to some of
14 the public comments which had to deal with the quality of an estimate
15 of the 99.9th percentile.

16 I think one could argue that choosing a distributional point from
17 which to compare margin of exposure could be driven by the science,
18 find some optimal rule for deciding what seems supportable by the
19 science that you're working with, and the margin of exposure process
20 is adjusted based upon where that percentile is and the quality of the
21 science that went into that exposure percentile.

1 I think that would potentially be a better solution than the
2 continued debate about the quality of the 99.9th percentile. And I
3 think I'll add that to my comments to you.

4 DR. KENDALL: Would EPA like to respond to that? Dr.
5 Roberts.

6 DR. ROBERTS: Yeah, Chris asked how the rest of the Panel
7 feels about the issue of including the violative residues from the PDP
8 in the assessment. And I guess I would weigh in in favor of including
9 them.

10 I think that as a follow up to some of our earlier conversation, I
11 think that this probably is an unavoidable consequence even of the
12 lawful use of pesticides despite everyone's best efforts. It's a human
13 exercise, and there's going to be a small percentages of times when
14 those levels are exceeded. And I think if we're going to make the
15 argument that our cumulative risk assessment reflects reality, I think
16 it's probably important to go ahead and include those small
17 percentages in our assessment.

18 DR. KENDALL: Any further comment or agreement? Dr.
19 Durkin.

20 DR. DURKIN: Yeah, I would like to simply endorse the idea of
21 putting the residues in. I understand why they're not there in terms of

1 not being able to address them perhaps from a regulatory perspective
2 and that does make a great deal of sense.

3 But we seem to have two tracks here, and we discussed this.
4 Are we dealing with a regulatory tool, or are we dealing with some
5 sort of a public health risk assessment? Do we have a problem here?
6 And if that second part is important, and I believe it is from what I've
7 heard, then I don't see a reason to exclude those residues. In fact, I
8 see every reason to keep them in whether or not they make a great deal
9 of difference. We're trying to reflect reality.

10 DR. KENDALL: Dr. Bull.

11 DR. BULL: He said it much better than I, but I agree with that.

12 DR. KENDALL: Okay. Dr. Rhomberg.

13 DR. RHOMBERG: I guess I'd like to take an agnostic position
14 on this, but with a little discussion.

15 It seems to me that the purpose of doing the risk assessment is
16 to serve risk management ends. So the real question is what risk
17 management options that are available and what kinds of analysis
18 would most inform them?

19 Now, you could imagine violative exposures, that being an
20 argument for including or for excluding violative exposures. And in a
21 way it sort of depends on some things about how inherent they are in

1 any kind of use of the agent as Dr. Portier was suggesting. Obviously,
2 to some degree that's true.

3 But if you put them in, you have to be very sure that you then
4 interpret the analysis accordingly. And if it happens that those
5 violations are driving the upper percentiles, it has to, then, be
6 acceptable to do a risk management solution that sort of takes that
7 into account and takes into account what perceived responsibility
8 there are for different parties to deal with the fact that that kind of
9 things occurs.

10 So if we put it in, we have to be very clear that the analysis
11 means sort of something different from a risk management point of
12 view. We can't play it this way one time; and then when the Agency is
13 going and making the risk management decisions, playing it the other
14 way and to try to say, Oh, it's incumbent on the Agency to make
15 regulations such that those things don't occur as well.

16 Whether they are not, is a complicated question that isn't really
17 about exposure analysis anymore. I think that if we put them in, the
18 analysis means something else; and it should be clear that we are
19 expecting a different use and interpretation of it by the EPA in the
20 regulatory arena as a result of that.

21 DR. KENDALL: Dr. Adgate.

1 DR. ADGATE: I mean not to beat the dead horse too hard. I
2 think it would be useful to point out the fact that tolerances are in fact
3 not health-based and that should provide you with some cover. And I
4 think that fact you are all quite aware of often gets lost in these sorts
5 of analyses. At least in theory what we're doing here is health-based.

6 DR. KENDALL: Dr. Portier.

7 DR. PORTIER: Following up on what Lorenz said, I guess the
8 only regulatory control that would convince me you should throw out
9 the violators would be one in which you were continually monitoring
10 these products, and if it exceeded the tolerance, you threw away the
11 product. If you didn't throw away the product but in fact mixed it
12 with product with lower bounds, lower levels, then that could, of
13 course, be incorporated into the sampling strategy for the PDP to look
14 at the question of what impact could would that have. But I think the
15 reality is those are the data and I would really encourage you to use
16 them.

17 DR. KENDALL: Would EPA care to respond to any of the
18 points made, or were they clear enough?

19 MS. MULKEY: I think we would like to encourage a little more
20 elaboration if there is going to be a discussion of some sort -- and I'm
21 over simplifying this -- trade off between choices about what part of

1 the distribution to consider regulating at and what kind of acceptable
2 or target MOEs we might work with. And we are mindful that that is
3 that's a mixed science and policy decision as you seem to be mindful.
4 But if you're going to discuss the idea of the intersection between
5 those two, do so in more that identifying it as an intersection, I guess
6 is what we're trying to say.

7 DR. KENDALL: Okay. Anybody like to comment on that?
8 Chris, do you want to comment? Lorenz? Go ahead and start, Chris.

9 DR. PORTIER: You know we've discussed this from the other
10 direction before with the SAP in terms of using the benchmark dose
11 and what happens with 1 percent, 5 percent, et cetera. On the side of
12 exposure, I think it's got to be the same thing. And I don't have any
13 fixed factors for you. I think it's a debate you have to have both
14 publicly and internally as to how you do the margin of exposure and
15 what constitutes a reasonably acceptable margin of exposure.

16 It's driven by a lot of things. In this case, instead of looking at
17 a directly toxic endpoint, you're looking at potentially a biomarker of
18 a toxic endpoint. And that weighs into your decision about how big or
19 small you want the margin of exposure.

20 I think the same thing is true on the exposure side of that
21 distance. In terms of, if you only have 10 or 20 or 13 samples from

1 which you're making your distributional assumption, you would want a
2 larger margin of exposure against a fixed point. And that pertains -- it
3 pertains to the variance of the estimate of the point.

4 If I choose a 99.9th percentile, I know the variance is going to
5 be large; and I know, to some degree, that my choice of that percentile
6 is driven a lot by tail behavior of my data set. So the bigger the data
7 set, the less of a margin of exposure I would want if I believe 99.9
8 percent is really safe.

9 If I believe 99.9 percent is safe and I'm going to set it at 90
10 because that's the best thing I can do with the data set that I have,
11 then I'm going to want some sort of factor in my head for this margin
12 of exposure that makes it a bigger margin of exposure. Because I
13 know chances are 10 percent of the population is somewhere above is,
14 but I'm not sure what, how far above that actually goes.

15 There are no easy answers in that question. But I think we have
16 to be as a Science Advisory Panel, we have to be clear where the
17 science can take you and where it can't. And by deciding on a margin,
18 deciding on a point of departure that's based science per se with
19 reasonable objective rules and recognizing that sometimes the science
20 pushes us closer to the tail of that exposure distribution and
21 sometimes it doesn't, I think that needs to be factored into the margin

1 of exposure rather than always choosing a fixed point, 99.9, regardless
2 of the quality of the information and a fixed margin of exposure
3 against that.

4 DR. KENDALL: Okay. That's pretty clear. Dr. Durkin.

5 DR. DURKIN: I was going to weigh in with something a lot
6 more simplistic. I think basically philosophically agreeing with what
7 Chris has said here.

8 We are talking about margins of exposure and talking about
9 these as things that can be basically set as a matter of policy. But I
10 think it's good to keep in mind that for a very, very long time, the EPA
11 and others involved in human health risk assessment have sort of
12 looked at the reciprocal, the hazard index of chemicals, that was in
13 turn based on a ratio of the exposure to the RFD, where the RFD was
14 something that was pounded out as a matter of science to the extent
15 possible.

16 And I think that this is -- you can still handle it as a margin of
17 exposure if you're comfortable with that; although I think the hazard
18 index approach is much more elegant. That's just my bias.

19 But I think the point is that we know a great deal about the
20 organophosphates. You have picked yourself an index chemical, and
21 we have, I think all, agreed that this is a reasonable approach and that

1 the relative potency method is reasonable. I don't think it is beyond
2 the scope of OPP to look at whatever choices that they would like to
3 make in terms of do we regulate at the, you know, 99.9 or the 99 or
4 whatever, and then to look at both animal and the human data that we
5 have, not simply methamidophos, but on the whole class of chemicals,
6 and come up with what is functionally an RFD or, if you're old an ADI.
7 That would indeed lead you directly to a margin of exposure that is
8 more science-based than policy based. And I think that would
9 probably be a reasonable way to go about this.

10 DR. KENDALL: Dr. Reed.

11 DR. REED: Maybe this is a good time for me to get something
12 clear. I really appreciate in this, whether it's uncertainty or a
13 sensitivity analysis or the material that we received, that you actually
14 present not just one slice of the distribution, 99.9th or whatever, but
15 that you actually present modal points.

16 I don't know. Are you thinking of doing that in the final
17 document, or are you thinking of just presenting it one point?

18 MS. MULKEY: In almost all our risk assessments, we present
19 these multiple points.

20 DR. REED: That's my understanding. Because to me, that's
21 important. I think a lot of problems or lack of understanding about

1 when you read a document is that it's really bothersome if somebody
2 just presents one point to me. It depends on how you slice it. The
3 high end gets sliced off or high end gets included and that kind of
4 problem.

5 Thank you for that clarification. I would like to see multiple
6 points being presented.

7 DR. KENDALL: Dr. MacDonald. Okay. Dr. Bull.

8 DR. BULL: Just a quick point. I think it's building on what
9 Chris started off here with. But one of the reasons I asked my
10 question related to this earlier was I think you pick your point on the
11 distribution, you may find that regulating at the 90th percentile will
12 have absolutely -- taking your margin of exposure at 90th percentile,
13 no matter what it is, the way I see the data there is some possibility
14 you'll never affect the upper end of that distribution because those are
15 going to get every more rare events as you get out. And when we
16 come to the drinking water thing, that's what concerns me. If there's a
17 hazard in drinking water, it's a very extremely rare event. And might
18 be an important event.

19 But you're probably not going to change that by either
20 adjusting, you know, within some reason between the 90th and 50th
21 percentile on the way you deal with residues on these different fruit

1 crops. It's probably not going to effect those extreme values.

2 DR. KENDALL: Okay. This will conclude our food exposure
3 assessment, unless there are any further questions from EPA for the
4 Panel.

5 Okay. At this point I'd like to move us to drinking water
6 exposure. And, Dr. Perfetti, would you like to introduce your
7 scientist.

8 DR. PERFETTI: To do the water presentation, we have Nelson
9 Thurman and Kevin Costello.

10 DR. KENDALL: Welcome.

11 MR. COSTELLO: Thank you give everybody a chance to get a
12 hand out.

13 Good afternoon. I'm Kevin Costello and today with Nelson
14 Thurman here we'll present a summary of the work we did designing
15 and performing the drinking water exposure assessment OP cumulative
16 risk assessment.

17 First, a road map of today's presentation. First of all describe
18 the preliminary results of our assessment so that everybody can
19 consider the rest of the presentation in that context. I'll describe the
20 background which led up to our assessment, first reminding you of the
21 data requirements we had for the exposure assessment. And then I'll

1 describe the knowledge we already had about the organophosphates in
2 drinking water, what data we had available, and just briefly review the
3 guidance we had received from the SAP in the past on the building
4 blocks we used for this assessment.

5 Finally, Nelson and I will discuss the drinking water assessment
6 as it appears in the December 2001 Draft. As we do, keep in mind the
7 two questions that we posed which deal with the two issues basically
8 presented here. First, the watershed modeling approach that we took
9 for the drinking water exposure assessment; and, second, the regional
10 assessment approach that we took which differs from the nationwide
11 assessments we've done for individual chemicals.

12 We'll try to do our presentation in a way that clarifies, builds on
13 those questions so that everybody understands better what it is we're
14 looking for.

15 Although Nelson and I are the ones giving the presentation
16 today, we're actually part of a much larger team that worked on this
17 basically from March until the December legal deadline and completed
18 it in time.

19 You can see that on the team from EFED beside us that we had
20 ad hoc teams that worked to come up with new modeling scenarios.
21 And Ian Kennedy worked to get the model development together. We

1 have some folks working on a separate track for an SAP on water
2 treatment effects. There are people from other divisions such as HED
3 and BEAD helped us with all the usage data and with building regional
4 assessments.

5 Now, the preliminary results of our exposure assessment
6 indicate that drinking water is not a major contributor to the total
7 cumulative risk from organophosphate insecticides. In fact, the
8 assessment showed that the exposure from drinking water was up to an
9 order of magnitude or more below of the food exposure.

10 Because of this result, it's very important to us that the Panel
11 think in terms of whether, as we give the presentation and from what
12 you've read, are there any systematic flaws in our approach that would
13 lead to over estimations or underestimations of possible drinking
14 water exposure. This is really important not only for the OPs, but this
15 is the tool, this is the first shot at the tool, that we intend to use for
16 future cumulative risk assessments for other pesticides families.

17 DR. BELL: Can I ask a question? I can't read this either there
18 or there. And I'm trying to figure where we're at. Is this dealing with
19 some level of residue?

20 MR. THURMAN: Actually, I think the whole part of that was
21 just to illustrate. Basically, when you get above the 95th percentile,

1 you see the similar trend.

2 DR. BULL: So it's above the 95th percentile.

3 MR. THURMAN: It's a higher percentile. And the whole intent
4 of it was just to illustrate that.

5 MR. COSTELLO: So as Dave Miller presented before, and as
6 SAP has seen before in the case study, the cumulative risk assessment
7 was done using a calendar-based approach. And daily exposures in
8 water are one of the building blocks of this approach.

9 Now, for the OP assessment we used the daily time step as
10 described before. But in future assessments, it could be -- that an
11 error there. Calendex will allow the 7-, 14-, 21- or 28-day rolling
12 averages we've gone through. And, also, as described earlier,
13 Calendex is the tool used to combine these exposures from the
14 different routes.

15 This is important especially for the drinking water and the
16 residential exposures because they have seasonal differences, they
17 have pulses of exposure that we consider in the assessment as opposed
18 to the food.

19 So we knew that in order to work with Calendex our water
20 assessment had to provide a distribution of daily concentrations for
21 the probabilistic exposure assessment. We had to account for

1 variations in time, daily, seasonally, yearly. We had to account for
2 variations in place because drinking water is much more of a local
3 phenomenon than food because of how food can be distributed the
4 around the country. And we needed to reflect the possibility of
5 co-occurrence of multiple OPs for cumulative assessment as they
6 occur together in place and time.

7 When we started this, we were not starting from scratch. We
8 already had, from the previous five years, more than 24 individual OP
9 assessments in the interim routes that had been done. From those, we
10 were able to derive the pesticides properties, the physical chemical
11 properties of the chemicals that we used to figure out environmental
12 fate.

13 And on top of that, because of those, we had regulatory actions
14 that had been taken voluntary cancellations, use rate changes for many
15 of these pesticides. And as was described before, as uses were taken
16 out, they were no longer considered in the assessment.

17 On top of that, we had a great volume of monitoring from
18 surface water and ground water; and to a lesser extent -- I'm sorry.
19 Can you go back one.

20 And we had the individual drinking water assessments that were
21 done in the aggregate human health risk assessments done for each of

1 these routes.

2 And finally, very importantly, we had SAP guidance along the
3 way as we refined our process for doing drinking water assessments.

4 Now, as we look through the available monitoring which had in
5 fact grown in volume since we did the individual assessments, we
6 found that in fact the OPs are found in drinking water sources.
7 Although this is not frequent, and they're usually not at high levels.
8 When considering all kinds of water monitoring, not just drinking
9 water, surface water sources, generally, seemed to be more vulnerable
10 to contamination by the OPs in a pattern that was seen not only in
11 nationwide programs like the NAQUA Program, but also in the state
12 programs because we actually contact all 50 states to see what kind of
13 monitoring they've done over the last 10 years or so.

14 Chlorpyrifos, diazinon, malathion were the most frequently
15 included; but they were also the most frequently found in surface
16 water studies, ground water studies and drinking water studies. We
17 found especially from the NAQUA Program that co-occurrence of the
18 OPs in water is likely. Multiple OPs were detected together in
19 individual samples. And this is not surprisingly related to usage in a
20 particular watershed.

21 In looking another the monitoring, however, we did find that

1 there some limitations to what was available for our purposes. Most
2 importantly, there is no single definitive study that can answer the
3 question what OP exposure is in drinking water. So we knew we
4 would need to look in monitoring in a weight-of-evidence approach
5 from several sources.

6 In looking at all the sources, we found that the monitoring
7 covering a number of sites but not all high use areas for the OPs. Even
8 in the largest programs, the ones that had the most intensive sampling,
9 sampling was not frequent enough to account for daily fluctuations.
10 And those programs, all of the programs, also have been done because
11 of constraints of how much they cost for a limited number of years.

12 Now, I mention that the chlorpyrifos, diazinon, and malathion
13 were the most often included OPs in monitoring programs. But not all
14 OPs were included in monitoring at all. In NAQUA Program included
15 nine currently registered OPs. State programs included some more
16 that weren't in the NAQUA Program, but some of the lower use OPs
17 were not in anything.

18 Few or no OP degradates of toxic concern were included in
19 most of the studies. Some of the very most recent studies are starting
20 to include those such as the pilot reservoir monitoring study that EPA
21 is doing with the USGS. And the monitoring that was available, even

1 the most recent data, does not reflect the most recent regulatory
2 actions that were taken. Like I mentioned, voluntary cancellations,
3 although they have been made official, still have the time before they
4 phase in.

5 So in the end, after looking at all the available monitoring that
6 we had, we concluded that we would not be able to base our exposure
7 assessment solely on available monitoring.

8 So if we were going to have to make up for the holes in the
9 monitoring assessments, the monitoring programs rather, with
10 computer modeling, this is where the guidance from the SAP we had
11 gotten in the past was particularly helpful. And I'm just really going
12 to run really quickly through some of the highlights of what we learned
13 along the way, what the guidance we received along the way.

14 In 1997, first taking our model, the PRZM-EXAMS model to the
15 SAP, we were told that it was a good tool, the best tool available, to
16 do our screening assessments. But that in the future, we should
17 devote resources to refining our assessment and concentrate on
18 surface water impacts, and as we go along, to use both modeling and
19 monitoring data in our assessment.

20 In 1998, we took a first refinement of this model to the SAP,
21 bringing our index reservoir scenario for consideration. This

1 adaptation of PRZM-EXAMS includes a scenario based on an actual
2 watershed, an actual reservoir, in the Midwest. Then having done
3 that, we moved from working with the watershed to trying to consider
4 what portion of a watershed would actually be cropped to get a
5 maximum idea of what portion of the watershed could actually get
6 treatment by pesticides.

7 The SAP actually approved of this, especially for major crops.
8 But due to concerns about scale differences, the size of the hydrologic
9 units, the eight-digit HUCs to drive these percent crop area factors, it
10 was not recommended that we use the PCAs for smaller crops or that
11 we considered percent crop treated with the pesticides without getting
12 further monitoring.

13 Now, this is important. As Nelson will describe before,
14 although the SAP did talk to us about this when considering aggregate
15 assessments, this was something that we felt we had to adopt to some
16 extent in order to do a cumulative risk assessment.

17 And then one last thing that was on the last slide, the SAP
18 recommended that we consider regional modeling, something that we
19 have done for this assessment.

20 In 2000, we went further in presenting proposed regression
21 modeling approaches that the USGS was and is developing which show

1 promise. But, again, it's just another step in the continuing refinement
2 of our assessment. These are still in process. And the SAP
3 recommended that we shift our focus to monitoring programs to
4 support model development and evaluation.

5 This is led up in December to the case study for the cumulative
6 risk assessment. That used WARP, the regression model; but we were
7 told at the WARP, while showing promise, was not ready for this kind
8 of assessment because it couldn't also do the daily time step. So
9 WARP was not used in our assessment at this time.

10 Finally, one more please. Something not directly in that line but
11 another ongoing and very important issue that we're looking into is the
12 effect of water treatment on pesticides. And the SAP recommended
13 that until we have enough data for any particular assessment to really
14 know what removal of a pesticide might occur and how much of
15 degradates, especially toxic degradates, might be formed, that we
16 should do our assessments based on raw and not treated water but that
17 we had to consider the impact of transformation products.

18 This is important for the OPs because we have limited evidence
19 that OP residues are in fact likely to not be reduced. But let me see,
20 the concentration reduced not speaking chemical by water treatment,
21 especially not reduced because we're talking mostly about chlorination

1 and oxidation processes.

2 There is, also, evidence for transformation of products that are
3 of toxic concern. However, as consistent with the SAP, because there
4 was not enough information for us to make quantitative adjustments to
5 our assessment, either to figure out how much of the parent goes
6 away, how much of toxic products are formed, and are how long they
7 last, we were not able to quantitatively include the transformation
8 products in, the water treatment transformation products, in our
9 assessment.

10 So with this guidance in our head, we went forward with a
11 watershed modeling approach for the cumulative exposure assessment.
12 We adapted PRZM-EXAMS in an attempt to estimate pesticide levels
13 in a small drinking water reservoir. By doing that, we derived daily
14 distributions over multiple years with weather being the variable for
15 12 regional assessments. By doing this, we're able to look at multiple
16 chemicals used on crops in multiple fields within the watershed.

17 For the cumulative assessment, we adopted typical use patterns,
18 typical rates, looking at the area that is actually treated with
19 pesticides. This is something that we have not done in our individual
20 assessments and we have to actually decide whether it's appropriate to
21 do in our individual assessments.

1 And, finally, for each of the 12 regions, we looked at
2 region-specific inputs. And I'll describe how we choose our scenarios
3 in just a moment.

4 Basically, when we decided that we were going to take a look at
5 regional exposure assessment for the cumulative assessment rather
6 than the national assessment that we did before, the first time we
7 considered how we were going to do it we sat around the table and
8 decided what would be the factors that would be important in figuring
9 out what these regions would be. And the very obvious ones that came
10 to mind were the OP usage. It's important to have an regional
11 assessment because some of the chemicals in the assessment aren't
12 used nationally. Some are. But some are used in very specialty crops
13 or just certain parts of the country. So we had to see which crops
14 were there that OPs were being used on and how much was being used.

15 Then we decided we really need to consider what the source of
16 drinking water is if we're going to do a drinking water assessment.
17 And some parts of the country, say, Florida, Southern Georgia, ground
18 water is the predominant source of drinking water; whereas in other
19 parts of the country, surface water was the main source.

20 Then we had to consider what the vulnerability of the drinking
21 water sources were. Some parts of the country, while having great OP

1 use, may not be all that vulnerable to runoff or to leaching. And we
2 wanted to take a look, on a regional basis, what the likelihood of
3 actual vulnerability was.

4 It just so happened that our friends in the Health Effects
5 Decision knew of a regional framework that had already been
6 developed by the USDA Economic Research Service. These are their
7 farm resource regions and this had the advantage we thought right
8 away of pretty much corresponding with what we were thinking about.

9 But on top of that, these are based on different farm types and
10 on previous work that the USDA did for separating the country in
11 ways that made sense, both for farms and for climate and for usage.
12 And, of course, they had advantage of ready-made names that we could
13 adopt.

14 Now, as you look at that, you can see that we have, we have
15 more than 12 up there. We did, in the end, combine some of the
16 regions based on the vulnerability. The basin and range was subsumed
17 into the Northern Great Plains as much as anything because of the
18 amount of OP use and where in that region the most vulnerability
19 seemed to be.

20 Now, once we had the regions, we still had to determine how to
21 do a drinking water assessment for an entire region. It does represent

1 a refinement over doing it for the entire country, but it still was a
2 problem that had to be addressed. So in building the cumulative
3 assessment on a regional scale, the first thing we did was to identify
4 high OP usage areas within each of the regions.

5 You can see, if you look at the regional boundaries, that say in
6 the Fruitful Rim Northwest you have multiple regions that have high
7 OP use, say the Wallamet Valley, the Yakima, and then along the snake
8 river in Idaho. So this was a good first cut.

9 But then if we go to the next slide, we built on top of that. We
10 took a look at how vulnerable areas were in each of the regions. How
11 vulnerable they were to surface water runoff and something that
12 wouldn't have come through on the computer. You see the dots. On
13 top of the vulnerability, we, also, took a look another where surface
14 water intakes were for drinking water sources.

15 So taking all of that into account, in the end for the modeling
16 approach, we came up with a set of areas within the regions,
17 watersheds that were going to represent each of the 12 regions. These
18 areas, then, have high apparent potential for cumulative exposure
19 based on the OP use, the number and the pounds of OPs being used in
20 those areas; they coincide with those areas high runoff potential; and
21 where surface is an important source of drinking water.

1 It is important to recognize that, although we choose those
2 areas to represent the highest cumulative exposure, they don't
3 necessarily represent the areas that have the highest exposure for any
4 single pesticide. But we still expect that the combined OP exposure to
5 be among the highest for each region. And on top of the four regions
6 like the Fruitful Rim Northwest, where we chose the Lamit Valley, we
7 did consider as best we can in our characterization, we attempted to
8 describe other important areas in those regions.

9 So for the Fruitful Rim Northwest, for instance, we went into a
10 discussion of the Snake River Valley, the geology, the hydrology of
11 the area, the type of use, the source of drinking water, which was
12 ground water. So that in an attempt to try and explain, again, why we
13 thought that the regions we choose were the best representation of
14 risk if the drinking water was a risk driver for any particular region,
15 which as it turned out, they were not, we were prepared to go to a
16 finer resolution than the regions and to try and look at what those
17 watersheds we choose actually represented within those regions and
18 try to get a more refined assessment.

19 So what we ended up doing by choosing these watersheds was
20 to tailor our assessment to selected areas. We used location-specific
21 environmental data for the regions that we chose -- the soil, the sites,

1 the local weather and the crops that were grown there -- and we
2 considered the major crop OP combinations within that area. And by
3 doing that, we looked at crops that actually occurred together. We
4 were able to look at different OPs used on multiple crops. And if OPs
5 were actually used in those particular regions for usage data. And
6 there the end, we did enough scenarios in an attempt to account for
7 about 95 OP use in each of the areas that we choose.

8 And Nelson will take over from that to give more details on how
9 we did the assessment.

10 MR. THURMAN: What I'm going to touch on here is not so
11 much how it built upon the SAP guidance in terms of what we were
12 doing for the individual screening assessments and how we tailored
13 these tools for use in the cumulative assessment. Kevin's already
14 talked about a regional framework, one of the big differences.

15 If you compare our individual assessments, we started at a
16 national level. We tried to pick one site that represented a high-end
17 exposure across the nation. In this case, we're starting in a regional
18 level and we're looking high-end exposure with each region with a
19 concept of, if we're okay on that site within the region, we're okay in
20 the rest of the region; if not, we need to burrow down further.

21 I'm going to talk about how we did our watershed-based

1 modeling and talk about the way we use the data which is a little
2 different than what we have in the individual assessments and how we
3 took a look at usage information.

4 There some people in this SAP that have been on some of the
5 water SAPs we've had and there are some of you folks are, at least to
6 me, new faces. So I wanted to briefly give you at least a concept of
7 what type of model we were using. For those of you who've heard
8 this, it won't be too long.

9 Essentially, PRZM, which is the Pesticide Root Zone Model, is
10 something that was developed out of EPA's ORD. It takes a look at
11 what happens when a pesticide is applied to a field. And it basically
12 follows the pesticide from the application to the field to the runoff
13 right to the edge of the water body. It's a field-scale simulation using
14 chemical movement, hydrologic factors. Accounts for ways chemicals
15 are transported, and it is very useful in terms of using it uses a lot of
16 chemical specific. We included both OP pesticide and those
17 toxicological concern it was primarily the sulfone (ph) and sulfoxides.

18 We did not include degradates that were not formed in the
19 environment, for instance, the oxons were not something we saw in the
20 environmental studies; that is something that we do see as a result of
21 the water treatment. But it is not formed in the environmental studies

1 we saw.

2 EXAMS, which is the Exposure Analysis Modeling System, is
3 another model developed by ORD. Basically, it takes over when
4 PRZM leaves off and looks at what happens once the pesticide reaches
5 the water body..

6 We had a few fixed inputs. The primary fixed input was the
7 geometry and hydrology of the reservoir itself. Essentially, as Kevin
8 mentioned, we used the index reservoir. Essentially, what we did for
9 each of the regions we picked up the dimensions, the hydrology, the
10 geometry, the size, and plot them in each of the regions.

11 Now this is going to be representative more of drinking water
12 reservoirs and drinking watersheds in the wetter parts of the country
13 than in the west where you're going to need a larger watershed to
14 supply that reservoir. It's also not going to be as representative where
15 you have artificial drainage or controlled drainage conditions, which
16 you also tend to see in the west.

17 It is a reservoir. It is not a flowing water body. Based on what
18 evidence we have, we expect the reservoirs tend to be a little bit more
19 vulnerable. Once again, we're looking at a site that, if we can make
20 the conclusions we did based on this site, we're not worrying about
21 other sites. But we do not know there were some limitations in terms

1 of that as we move in different regions in the country. And that's one
2 of the reasons why we continue to go back to feedback on what the
3 monitoring showed.

4 We had a number of variable inputs. As I mentioned early, the
5 chemistry, chemical properties, were specific to those chemicals. The
6 weather, the site, environmental crop, and usage information are
7 specific to each of the assessments areas. So in that way, we are
8 tailoring to things that actually occurred in the area where we did the
9 assessment.

10 What you see here, in case you can't see -- what you have is
11 concentration on the Y axis, and you have time on the X axis. And,
12 basically, you're looking at a 10-year span here. What we get as an
13 output of a PRZM-EXAMS are daily distributions of concentrations in
14 water over this ten-year -- in this case, a ten-year period.

15 I want to contrast a little bit because NRDC raised a concern
16 about one thing we do differently, which, as they pointed out, we use a
17 peak estimate individual screens. Actually, what we use when we do a
18 individual screen is a higher percentile what reflects a one-in-ten-year
19 concentration that we would find over the period.

20 And I forgot to mention, most of these sites we had up to 36
21 years of weather data. So we would run this simulation over a 36-year

1 period. In effect what we're doing when we do these simulations,
2 we're holding use constant and varying the weather from year to year.
3 So the variations you see from year to year reflect differences in the
4 weather and runoff that we get as a result of that.

5 For an individual screening assessment, we might use this one
6 value. And this red line there. And in effect what we're doing for that
7 assessment is we're assuming that this is a concentration that occurs
8 every day. What we're doing in this more-refined assessment that
9 we're doing and looking at multiple chemicals is we're realizing that
10 that concentration doesn't happen every day. You get your daily and
11 seasonal and yearly variations. So we're capturing that full range of
12 concentrations that you get.

13 We're also preserving the time component. We do know that in
14 any given year the concentration of pesticide you might see in water
15 on June 1 is going to be related to the concentration you had the day
16 before and the concentration you had the day after. So there is a time
17 relationship that we're able preserve by going to this yearly
18 distribution; and we're able to preserve Calendex to pull those
19 exposures in.

20 This one did not come out very well. I think we were so
21 ambitious to make sure that you could see it that we overloaded the

1 memory on the computer.

2 You should see at second distribution superimposed in here.

3 The intent, the point of that, I can tell you is that with a cumulative,
4 we're looking not just at one chemical; we're looking at multiple
5 chemicals that are going to have uses on different crops; their timing
6 of application is going to be different. We have to find a way to take
7 all of this into account.

8 Kevin mentioned briefly how as we use the use information and
9 zoomed in on an assessment area in each of the regions, we tried to
10 make sure that we captured all those OPs that would actually be used
11 in the same watershed. For instance, to use as an example, the
12 Northwest Fruitful Rim, we found that OP use on potatoes tend to be
13 concentrated primarily in Idaho. And OP use in apples tend to be more
14 in Washington. So we're not combining those two areas since they
15 don't actually physically occur.

16 The other component the co-occurrence is the time of use. As I
17 go forward in this, I will try to explain how we did try capture those
18 windows of application so that we could separate that timing as much
19 as we could accurately do with the data we had.

20 One of the big departures between what we have brought before
21 this SAP in the past and what we were bringing forward in terms of

1 this cumulative assessment is how we use the PRZM part of the model.
2 PRZM is a field-scale model. That basically carries a lot of baggage
3 with it. It assumes that we can take the field scale and scale it up to a
4 small watershed and not loose too much in the estimates.

5 We know that there are some assumptions that go with that.
6 We're assuming a single soil in the watershed, the crop and the
7 management practices are homogenous in that area.

8 For the cumulative assessment, we basically went back and used
9 PRZM as a field-scale model. But what we basically did is we
10 simulated multiple fields in the watershed. One of the things to keep
11 in mind is that, while we did this approach and we feel it's something
12 that does reflect what you might find is happening in the watershed,
13 we still don't have any way of giving a spatial distinction within the
14 watershed.

15 If you remember in the earlier slide of the pictures, the
16 conceptual drawing of that watershed and reservoir, we basically don't
17 have location-specific information there. We're assuming the crop
18 that's used covers a certain percent of that area, but the percent of
19 area is evenly distributed throughout the watershed. So we're not
20 distinguishing between crops that may be grown in the upper end of
21 the watershed versus those crops that may be concentrated in lower

1 end.

2 It also assumes that all of the runoff flows into the water body.
3 We know those are the two limitations that we in that. We do feel that
4 by simulating multiple fields, it better reflected what we needed to do
5 with the cumulative.

6 We, also, had to have a way to take in the fact that we
7 understand that not all of any watershed is going to be treated with
8 OPs. Those areas that are treated, you're going to have different
9 crops treated with OPs at specific times and specific rates and specific
10 frequencies. I'll say right now, the tools to do that are probably a lot
11 easier to do than getting the data that can do that. And one of our
12 challenges was how to pull this data together and use it to the best we
13 could. And in response to, I think, Daniel Botts comment, we're
14 hoping that we used the appropriate data. And we'll try to explain to
15 you what we did use. And we hopefully used it appropriately as we
16 did that assessment.

17 One of the things I do want to say is the advantage of simulating
18 multiple fields in a watershed, as we did, is each field may very well
19 have a different soil and a different crop. And so we are getting a
20 little bit more a reflection of a little more heterogeneous watershed
21 than we can using it as we did before.

1 This picture happens to be in the document and it looks better in
2 color than it does in black and white. Essentially, what I can tell you
3 is that that map shows a percent of the crop areas taking a look at, by
4 on a watershed basis, what the percentage of each of those watersheds
5 are in agriculture.

6 You can't tell whether the gray tones there, but your highest
7 concentration prejudice of agriculture occurs in the watersheds that
8 are in the Midwest. And the lowest is, obviously, in the Basin and
9 Range. This is where your highest concentrations are.

10 We used something we've called a cumulative adjustment factor
11 approach to account for the relative contribution of each OP in crop
12 use. We did this in terms that we had to take into consideration both
13 the recommendations and the concerns of the SAP on the percent crop
14 area factor that we brought forward to them. And I'm going to explain
15 to you how we did this so you can take a look and see whether it
16 makes sense. We think it makes sense, but it's one thing we want your
17 feedback on as we go along.

18 One of things I will say is that one of the earlier
19 recommendations of the SAP was that, when we started looking at
20 percent crop areas, we should do this on a watershed basis. And it
21 makes sense on a physical basis because we're looking at, we're

1 dealing with watersheds.

2 The thing to keep in mind the data is collected on the basis of
3 geographical and political boundaries. In other words, most of it is
4 collected at a county or state level, not on a watershed level. So you
5 need to take some way to translate that.

6 We brought forward an approach in 1997 for applying a percent
7 crop area factor starting with county level ag census data. In the '97
8 presentation, we used the 1992 ag census. We now have the 1997
9 agriculture census available which is one of the recommendations the
10 Panel was, as soon as it was out, to use the most updated information.

11 We, basically, overlaid those with watersheds and used GIS to
12 get that spatial distribution within the watersheds. Kevin mentioned
13 what we had available for GIS were 8-digit hydrologic units, which
14 tend to be fairly large. They average 367,000 hectares in size. And
15 you compare that with 172-hectare watershed we were using, you can
16 see that, at least for the smaller drinking watersheds, you get a lot of
17 them and you can get lost in those large HUCs.

18 One of concerns of the SAP was that while you may have minor
19 uses that don't add up to a big percentages in these large watersheds,
20 those minor uses are often clustered and they may be clustered in a
21 smaller watershed where they have more of an impact then they did on

1 a larger scale. So that was one of the challenges we had in trying to
2 convert this data.

3 We, also, were trying to keep in mind the caution against doing
4 too small a PCA for that reason. What we decided to do is come up
5 with a cumulative OP-PCA. So for each of those 12 regions as you
6 saw, we derived the percent crop areas for the total agriculture using
7 the '97 ag census data.

8 We then took a look using the latest national agricultural
9 statistics service data which is collected on the county level. We took
10 at look at agriculture land that were in crops that had registered OP
11 uses in that area. And we came up with that percentage. So we
12 essentially adjusted your total agricultural PCA by your percentage of
13 the aggregates from the OPs and came up with a cumulative OP-PCA.

14 This is an illustration that the numbers you see down there are
15 based loosely on an earlier version of one of the regions we were
16 looking at. I round them off to make it easier for me to do the math
17 and to explain what's going on. One of the challenges we had, if you
18 look at these total acres, they are total acres in the assessment area,
19 which is a lot larger than what you're looking. This is one of the
20 reasons why we went to a percentages so we could use that percentage
21 as a way of scaling down based on the area.

1 In this particular area, we're looking at a cumulative OP-PCA of
2 50 percent. Basically, 40 percent of that area in that region were in
3 crops that had registered OP uses.

4 Now, if you keep in mind that not all -- we know that in any
5 given year, not all of those crops are going to be treated with an OP.

6 It's further complicated by the fact, if you go to the next slide,
7 that these crops may be treated with multiple OPs. Some OPs may be
8 used on more than one crop. We used a second concept which was a
9 percent acre or percent-acre-treated factor. This basically used the
10 acres treated, which we collected state-level data, as a way of
11 determining how many acres of the total -- for instance, how many
12 acres of total corn were treated with a particular OP.

13 Now, this acre-treated doesn't take into account the fact that
14 you may have more than one application that goes in that area. And if
15 you were to look over at, for instance, the beans, which you see here,
16 is a particular case we had two different OPs that were basically used
17 on the entire crop at different times.

18 What's not reflected in here is timing and I'll get at that again in
19 just a little bit. But we used this concept to derive a cumulative acre
20 cumulative adjustment factor which combined both the percent-crop
21 area and the acres treated based on the slide that -- based on the one

1 that had the map that you couldn't see.

2 I know you can't read all of these. What I want to just point out
3 is that when we did this, by combining both the acre treatment and the
4 percent-crop area, this gave us a way to distinguish between the
5 relative contributions of each OP and crop use within that watershed.
6 And so we use this cumulative adjustment factor as a way of making
7 that adjustment.

8 So what we did is that we ended up with each of the crop OP
9 uses that we identified in the assessment area, we ended up with daily
10 distributions. And we still needed to combine these individuals
11 distributions for different chemicals together. So what you see here in
12 each of these distributions is that we put them on equal area. We use a
13 crop-area factor, the cumulative adjustment factor, to put these on
14 equal footing in terms of the area contribution they made in the
15 watershed. We used the relative potency factor, we talked about
16 earlier, to put them on a comparative basis so that we could combine
17 this so that we'd end up with any regions a single distribution over up
18 to 35, 36 years in methamidophos equivalence.

19 And so what you see there, in fact, you will see in these multiple
20 peaks in a given year, which basically reflect different timings of
21 applications of different pesticides.

1 Now, there are some assumptions and issues that come out of
2 the way we did this approach. One again, we tried to address the SAP
3 concern about the fact that data came in different scales. We're trying
4 to take county and state level data and apply it to a watershed. And
5 the fact that the size of the watersheds we had that we could work
6 with to do this are a lot larger than the more vulnerable drinking
7 watersheds. And we're trying to address the fact that some of those
8 crops cover small areas.

9 Our feeling was that by using a cumulative OP-PCA, starting
10 with the total agriculture and adjusting for total OP uses, we don't end
11 up with a number of small, separate percent-crop areas that may
12 introduce more error into it than the combined PCA in that regard.

13 Secondly, we said we still have some issues on applying an acre
14 treatment adjustment. The percent-crop treated is complied to state
15 level. And there's a couple exceptions in that one is California where
16 they, California Department of Pesticide Regulations, basically has a
17 census in that they require all users to report what they use and when.

18 The other one is whenever we were looking at the Willamet
19 Valley, we also found some use data specific to the Willamet Valley
20 Collective, actually folks at Oregon State, that we were able to use.

21 When we take this information to state level and we try to apply

1 it at a watershed within a state, there's a number of assumptions
2 embedded into this. And one of the big ones is that we've assuming
3 that the data that's collected at state level, the percent-acres treated,
4 is uniform across all watersheds in the state. There's also an
5 assumption of uniformity in time. I'll get to that in a little bit.

6 What we know is that pesticide pressures are not necessarily
7 uniform. And so what you're going to find is that where pesticide
8 pressures are great in a particular year, you're going to see more acres
9 treated, possibly at higher application rates. Where they are less,
10 you're going to see less acres treated. So there are some concerns in
11 doing that.

12 One of the other things as we took a look at that is we, also,
13 realized that crops aren't uniformly distributed across the entire state.
14 So in those areas where your crops are clustered in a certain area and
15 where your use is clustered together, there may be less of a variability
16 than in other cases. And that may be one of the differences between
17 some of the minor crops and some of the crops like corn which tends
18 to be more uniformly distributed in the Midwest.

19 Our assumption in doing this is that this is probably more of an
20 issue when you're looking at a single crop, single OP use in a single
21 pesticide than when you're looking at an area where you're looking at

1 multiple crops, with multiple pest pressures that are going to vary, not
2 necessarily all at the same time and over multiple OP uses.

3 We did take a look in one area to see -- and one effect we got
4 some reflection of maybe some of the variability we might see in this.
5 In the Northern Great Plains we focused on the Red River Valley
6 which tends to be where the highest total OP use was in that region.

7 We identified high OP use areas on either side of the Red River
8 in North Dakota and Minnesota. As we start taking a look at some of
9 the OP use information, you could see a difference, both in terms of
10 application rates and the percent-acres treated between those two
11 states. Our feeling was that difference was more of a reflection of the
12 data collected at the state level in those two states than of actual
13 differences on either side of the river in that Red River Valley.

14 We did do comparisons using North Dakota information and
15 then using the Minnesota information to see how much of a difference
16 that makes. And what we did find is that at your highest percentiles --
17 in fact, anything above 90 percent, there was roughly no more than a
18 10-percent difference.

19 And we're talking about single parts-per-billion concentrations,
20 so we're looking at no more than a fraction of a part per billion
21 difference with that. A lot of that was the fact that, once again, we're

1 looking at a combination of uses. So there was not just one single use
2 that was pulling together.

3 We used survey data to get at the use. We uses USDAs
4 National Agricultural Statistic Service information on pesticide usage
5 to give us the information on use. We did not attempt to forecast.
6 Except for the fact that we did exclude any uses for which regulatory
7 action has been taken to cancel.

8 We also focused on the most recent year of the use data. One of
9 things, if you look at the data, and particularly if you look at each of
10 the regional assessments, you will realize that some of those dates --
11 you have different dates; different years. That's because the NASS
12 collects the information at different times.

13 Field crops are collected every year, but fruits and vegetables
14 are collected in alternate years. We may have had to go back more
15 than one year to get equivalent data. The other thing to keep in mind
16 what we did use was not your maximum application rate, but we used
17 an average. And that was basically the average of the respondents of
18 the survey within that assessment area.

19 We took a look -- a number of OPs have more than one method.
20 They can be applied to either aerial or by ground. We focused on the
21 dominant method of application in that area. While our primary source

1 was NASS, we did, where we could find local sources, we did
2 supplement that information in those local sources and we have
3 documented that in the assessments.

4 We still need a way to account for the time component of the
5 co-occurrence and in the timing of pesticide applications are going to
6 have a big influence, particularly the timing in relation to when a
7 runoff event occurs.

8 So we took a look at what information we had. This is a
9 distribution for the Central Valley, California, which we use the in the
10 Southwest Fruitful Rim assessment. This happens to be the area that
11 had the most OP use and the most crops with OP uses.

12 And as you can see here, you got a distribution of applications
13 the different colors are the different pesticides, have a distribution of
14 applications throughout the year.

15 One thing to keep in mind is the data in California is a little
16 different than what we had elsewhere in the fact that California does
17 require reporting of every user in terms of how much you used, when,
18 what, where. So we could get that at a county level, and we could get
19 that across the year. So that data reflects more of census than a
20 survey.

21 And that's the one differences that we had there. This, in effect,

1 made it a little easier for us to do an assessment in California terms of
2 timing.

3 DR. BULL: Quick question on that. Those are cumulative
4 curves. I mean you've got one shade.

5 MR. THURMAN: Yeah. Those are cumulative curves. It may
6 have been easier if we'd had another one where -- but this just shows
7 you the more complex end of it.

8 In other areas, we only had surveys. So we had to find a way --
9 we didn't have this type of distribution information. We usually had
10 something tied to a window of application. We had to find a way to
11 find that window in a way that would try to as accurately as we could,
12 reflect those actual differences in applications.

13 What you'll see when you look at the document is there are
14 different ways we accounted for this temporal variability. In
15 California, where we had the census, it showed a distribution across
16 the year. What we ended up doing was we selected five dates along
17 this distribution with each date representing 20 percent of the total
18 applied use. So, essentially, you had quintals for each of your crop OP
19 combinations.

20 In the other regions where we didn't have that specific timing,
21 what we usually had was information reported by a particular window.

1 It was either management windows or times of the year. We used
2 USDA chemical usage information, their planning harvest reports,
3 crop profiles; we talked to regional specialists or local specialists in
4 those areas to try to define that window of the application as narrowly
5 as possible.

6 If we had a pesticide that had a single application of a crop but
7 we had no distribution information, for instance, if we had a pesticide
8 that we knew was applied at planting, but there was no other
9 information on the distribution of those applications, we would take a
10 look, go to the local area, find out when the window of planing was.
11 And then we would apply this pesticide at the beginning of that use
12 window.

13 If we had a single application but we had some type of
14 distribution window and we were able to define an active window
15 within that, then we would select the midpoint of that active window
16 to apply the pesticide. If we had pesticide that had multiple
17 applications, then we tried to distribute that evenly across the use
18 window.

19 Once again, this is given the fact that the information we had.
20 We felt this was as tight as we could get the windows to do that. And
21 given the data scales, it was difficult for us to get tighter values.

1 There is some conservatism when you saying we're applying all that
2 single application on a given date on the same data in a given
3 watershed as opposed to saying, well, we're going to distribute that
4 application out using a uniform distribution within a use window.

5 However, we don't think that was unreasonable conservatism
6 when you start looking at the size of the watershed we were looking
7 at. When we're looking at adjusting those fields for the percent crop
8 area and the percent acres treated, it made more sense that these fields
9 were the size that all those applications would actually occur on a
10 single day rather than at different days on there. So we felt like there
11 was some conservatism to it, but it wasn't an unreasonable assumption
12 to make.

13 What we found is that when we did these and in each of the
14 regions we generally found that there were one or two chemicals that
15 were drivers in terms of the water exposures. This is also in the
16 Central Valley of California. One of things that we found here is these
17 cumulative distributions that we pulled together in methamidophos
18 equivalents, once again, were a function both of the concentration of
19 the pesticide in water and the relative potency factor.

20 Disulfoton, which is the one that you see dominating the curve,
21 and once again this is a cumulative curve, has a higher relative potency

1 factor than these other OPs that you see here. That helped skew that
2 curve. We did find, as we went back through there, is that we were
3 able in most of these regions to get some separation of peaks and time
4 so that we weren't artificially adding peaks together that wouldn't
5 actually occur together. And the fact that in each of the regions, we
6 were pretty consistent that there were only a handful of OPs that were
7 drivers. And these tended to be the type of OPs that we saw in the
8 monitoring data suggested that we weren't too far off.

9 Okay. You'll be happy to know this is the last slide before the
10 questions.

11 We kept trying to go back and compare what we did in the
12 modeling to the monitoring data. When you look at the report, one of
13 things where the comparison occurs is in each of the regional
14 summaries, each of the regional write-ups we wrote up a comparison.
15 What we're planning to do to make life easier, because of some
16 comments we had, is to try to pull that together in one place for all the
17 regions together to make it easier to find it all at one time.

18 One of the challenges we had when we were comparing what we
19 did in the modeling to the monitoring is that, A, there is no single
20 definitive study. A lot of the monitoring studies we had were on
21 running water from streams and rivers. There were a few, a couple of

1 studies, that focused on reservoirs. But these did not focus across a
2 broad geographic range or across a broad time.

3 We took a look at everything we could. We tried to compare as
4 much as we can, particularly looking at the peaks that we estimated
5 for each of the individual pesticides in those regions to the highest
6 detections that were reported. We also tried to take a look what I
7 would call an "equivalent frequency detection." Each of those, in the
8 monitoring studies, each of those OPs has a limit of detection.

9 When you're in PRZM-EXAMS, it can carry it out well below
10 the limits of detection. But we could, basically, take a look at what
11 percentile fell above or below that limited detection you would see in
12 the field to see whether or not how we were doing in terms of
13 estimating or overestimating.

14 One of the things, because they're not necessarily easily
15 comparable, it's difficult to draw definitive conclusions and point this
16 tells us one thing or another. Because we looked at 12 different
17 regions, we were -- give us a chance to take a look at what each region
18 tells us.

19 So if we were looking at something -- it gives us another way of
20 kind of discerning whether or not we were having a function of
21 compensating errors or fortuitous results or whether we may actually

1 be on to something.

2 What we found is the other thing that we need to keep in mind is
3 we did not have monitoring data for every OP. So we had to assume
4 that what we had reflected in comparing for the monitoring that was
5 there would also be have been reflected for the others that weren't
6 monitored.

7 In each of the regions, we did find a few known detections of
8 one or more of the OPs that occurred at levels that were higher than
9 what we would have estimated. We were looking roughly at order of
10 magnitude differences, in part because the results that we had showed
11 the drinking was and order of magnitude or more lower than food
12 exposure.

13 So we took a look at order of magnitude differences. And to be
14 honest with you, when you're doing some of these comparisons,
15 getting much closer, gets a little queasy, anyway.

16 We did find that some of these had reported monitoring values
17 that were higher than what we estimated, but there were also some
18 where our estimations were an order of magnitude more greater than
19 what we found in the monitoring.

20 We did not find a consistent trend in one way or another. We
21 also found that there were a number of OPs that were fairly close to

1 each other in each of those regions.

2 In the questions that you're going to respond to after the public
3 comments, we were asking you about whether you say anything where
4 we may have significantly underestimated exposures, in part, because
5 that's the way the results of the study came out. We're just as
6 interested in anything you see that might suggest that we're significant
7 overestimating exposures, too, so that we can take that into account
8 on future assessments.

9 And I think the next ones comes to the questions.

10 DR. KENDALL: I don't want to have those read at this time.
11 First of all, any points of clarification from the Panel for the
12 presentation?

13 DR. MCCONNELL: I'm sorry. I missed the first few minutes.
14 Maybe you covered this, Mr. Thurman. I noticed in your geography
15 plots up there that one of high use areas is in Florida. And I got to
16 thinking about in a situation where you have soils, poor soils, shallow
17 water tables, have you looked at the ground water; or did you cover
18 that and I missed it?

19 MR. COSTELLO: We considered it. We made the decision
20 looking at it first -- well, one step back. Again, one of the reasons
21 why we separated regions the way that we did, was to separate those

1 regions that had ground water as the major source of drinking from
2 those that had surface water as the major source.

3 Next, we came to the conclusion that surface, generally, would
4 be more vulnerable as a drinking water source to contamination from
5 the OPs. For what data was available, there was clearly a lot more
6 contamination of surface water and, just as importantly, much more
7 cumulative co-occurrence of OPs in surface water. Something that we
8 don't have evidence for in ground water.

9 But compounding that is the fact that beyond the fact that the
10 monitoring is not enough for ground water to allow us to get the daily
11 distributions, we actually don't have a tool like PRZM and EXAMS
12 that would allow to us do the same thing for ground water. So it is
13 one of the uncertainties of our assessment, especially for places like
14 Florida, that we had to do a surface water assessment and assume that
15 the concentrations that we would come up with, the exposure we
16 would come up with, would exceed it.

17 There are reasons for certain individual chemicals that calls that
18 into question to some extent. In Florida in particular, one of the OPs
19 has, in certain regions, been found at higher concentrations that we
20 had in our surface water assessment. This is one thing that we
21 describe in our risk characterization as one of our uncertainties.

1 On top of that, in all of the regions, including the ones in which
2 surface water is the dominant source of drinking water, there is still a
3 significant portion of the population that derives drinking from
4 shallow, private drinking water wells.

5 Again, this is why we are hoping in the way that we did our
6 modeling scenarios that we have come up with what is likely to give
7 the highest cumulative exposure to OPs as opposed to potential
8 individual higher exposures to individual OPs in shallow drinking
9 water.

10 MR. THURMAN: One other thing I'd add to that is this is
11 where the relative potency factor also comes into play when we're
12 looking at cumulative impact.

13 In Florida it turns out that where we did focus on surface water
14 -- and there are not many surface-water intakes in Florida; we know
15 that -- there happened to be a couple of OPs -- and I'm going to blank
16 out on which ones -- that are used on sugar cane that have relatively
17 high application rates and had a much higher relative potency factors
18 than the OPs that we were finding in ground water. So when you
19 started looking at it from a cumulative impact and you take into
20 account the relative potency factor, we did feel that the surface-water
21 assessment is going to be protective in that regard.

1 MR. COSTELLO: And this is one of the reasons why I
2 described -- when we figured what areas had the highest OP usage, if
3 we had not chosen them to be representative of the entire regions, we
4 made some attempt to characterize the likelihood of drinking-water
5 exposure in those regions. So if you take a look at the Mississippi
6 Portal, for instance, which, like Florida, is an area that has much more
7 of a population deriving its water from ground water than surface
8 water, a detailed discussion of the geology of the area of the aquifers
9 in the area will let you see that the greatest portion of people that
10 derive their water, at least from other than private wells, are getting
11 water that is protected by confining layers between the aquifers.

12 It does not write off the risk especially to people on private
13 wells. But just to say that we made our best attempt to account for
14 the vulnerability of the drinking source other than the surface water
15 that we used in our models.

16 DR. KENDALL: Dr. Bull.

17 DR. BULL: A couple points of clarification. The issue you
18 raise at the end, wouldn't you want -- since this was a conservative
19 approach that you were taking, are you a little bit surprised that you
20 had some things that are higher than what you predicted because I
21 would have guessed this scenario would have been more protective.

1 MR. THURMAN: We are going --

2 DR. BULL: I would expected most actual monitoring data to
3 come in lower.

4 MR. THURMAN: We are going back through and taking a look
5 at each one of those and trying to come up with a rationale, see if can
6 identify a reason why there may have been up.

7 In some cases, we do know that they are from uses that --
8 they're uses in the area that are being canceled. So we know that there
9 is that type of a contribution. In some cases what we found that they
10 are in areas were not necessarily, the monitoring was not necessarily
11 directly located where the major use, where our cumulative impact
12 was.

13 In one or two areas we do find that there were some watersheds
14 where the monitoring came from that are high ag use but are not
15 representative drinking water -- they are not drinking water sources.
16 So those are some of the things we are going back and taking a look at
17 to see if we can...

18 MR. COSTELLO: But if I may. Some of the monitoring that I
19 did find, although not direct drinking water monitoring, something to
20 keep in mind how limited direct drinking water monitoring is for the
21 OPs. But even if they were not drinking water samples, they were in

1 potential drinking water sources or in small streams that fed them.

2 DR. BULL: I'm going to try to keep this to points of
3 clarification.

4 One of things that impressed me is those areas that you got are
5 pretty heterogeneous within those I areas. I live in one of those areas
6 as everybody else in the room is. But I know what they are.

7 I heard you talk about weather patterns, but I didn't hear you
8 talk about irrigation. And irrigation is a big issue on runoff because
9 you're going to get runoff from irrigated fields. And if you're just
10 using -- are you taking that into account?

11 MR. THURMAN: We did take irrigation into account. There
12 were a couple of regions where, you know, PRZM does have an
13 irrigation routine. And in some cases, we've had to do some
14 calibration of that irrigation routine. So particularly in the Central
15 Valley, but in a couple other areas --

16 DR. BULL: In our part of Washington State, you don't get
17 runoff if it's not from irrigation.

18 MR. THURMAN: Yeah. To be honest with you, one of reasons
19 why we are looking at that is taking a look at where your runoff was
20 going to occur. And we do realize that -- that's one of things we know
21 that, where you have controlled drainage or human influence drainage,

1 and in this case irrigation, is this is going to be weaker in terms of
2 trying to capture that effect on it.

3 DR. BULL: And there's probably limited places you can
4 actually measure it.

5 MR. THURMAN: Now the thing that helped us on that is we
6 did do -- we were able to do some comparisons from USGS NAQUA
7 data and different -- particularly in the Northwest Fruitful Rim, in
8 each of those major use areas, there were some NAQUA studies that
9 were conducted at the same time. And so we were able to do some
10 comparisons with the monitoring data to see where the relative
11 impacts were likely to be. So that helped guide us in selecting the
12 site.

13 DR. BULL: There's another kind of issue that runs in a funny
14 way, too. You mentioned the potatoes in Idaho. I've heard -- I'm not
15 sure it's true, but I think we do more potatoes in Eastern Washington
16 than they do in Idaho now.

17 MR. THURMAN: I apologize for that. But that's true.

18 DR. BULL: But the issue of shifting crops, I mean, there's also
19 a good -- you can also get applewood which is very good for the
20 fireplace in Eastern Washington because a lot of people are taking
21 orchards and they've shifting to different locations along the river.

1 MR. THURMAN: Certainly that's --

2 DR. BULL: How do you take that into account? These are big
3 shifts going on.

4 MR. COSTELLO: Well, you know, the usage data that we had,
5 the attempt was to have it for as recent as possible, and the monitoring
6 data as well, to keep it somewhat recent. You know, along those lines
7 is why we described how things such as -- we know that the
8 uncertainties say that in the usage that is reflecting a certain number
9 of years that the monitoring can't reflect canceled uses or other OPs
10 that might come in to replace cancelled uses.

11 DR. BULL: That's what bothered me about taking out the
12 canceled ones.

13 MR. THURMAN: Once again, we weren't forecasting. But I
14 will say that in each of the regions, as we were looking at the sites, we
15 were laying out what are the crops and what are the uses. And the one
16 that strikes my mind, comes to mind right now, in Eastern Uplands we
17 were looking at an area in Kentucky which did have tobacco use. That
18 is a crop in, at least in Kentucky, is going down in acreage and OP use
19 is going down.

20 And the other alternative was apples which is in another part of
21 the area which was steady or going up. And so that's one of the things

1 we did take a look at. It was more of in each of the regions as we're
2 trying to decide where do we focus the assessments. We would look at
3 that, but sometimes that's hard.

4 DR. BULL: The final question I had along the same kind of line
5 is you said the state usage rates are state wide but you only spread
6 that over crop areas; right? You didn't spread that over --

7 MR. THURMAN: Only over crop areas.

8 If you look at the use information that is based on surveys. So
9 they are selecting farmers across the state that reflect -- they're
10 reflective of different farm types and sizes and they're actually asking
11 them what is your application rate, and how many times do you apply
12 it on this. So that survey -- so what we're getting and let's say we get
13 an average is actually a reflection of actual survey response. And it's
14 aggregated at a state level.

15 DR. BULL: But the apples in Washington, in Yakima, but most
16 of them are probably up in (inaudible) Valley and up in Columbia and
17 up into Canada which is another. The (inaudible) Valley up in Canada.
18 So those are all very concentrated. And then you get out in other
19 areas and they're grains and potatoes and things up on the flat.

20 MR. THURMAN: Did it does take into that.

21 DR. BULL: It does?

1 MR. THURMAN: Yes.

2 DR. KENDALL: Any further clarification from the Panel about
3 this issue?

4 DR. CAPEL: Yes. As part of the introduction you showed up a
5 watershed exposure plot for drinking water. I'm not quite sure exactly
6 what that represents. I have two question. One is: Is it the output of
7 PRZM-EXAMS with no adjustments for treatment?

8 MR. THURMAN: Okay. It's actually more than -- the output of
9 PRZM-EXAMS, we did not adjust the treatment. So basically we're --
10 we did find anyway to quantitatively do that.

11 But it also takes into account where Dr. Smith Mr. Dave Miller
12 were talking about the CSFII dietary data. Part of that data includes
13 drinking water consumption. So you get your levels in the water,
14 which are your residue part of that, but you also have a consumption
15 part of that to take into account in that MOE plot that you saw,

16 DR. CAPEL: So I guess the other half of the question is: Is it
17 based only on the parent compounds, or are the transformation
18 products also included in that?

19 MR. THURMAN: It is based on parent compounds and
20 transformation products as it occurs in the environmental
21 transformation products. So basically the parents...

1 DR. CAPEL: So it's part of the PRZM-EXAMS model that
2 you've got --

3 MR. THURMAN: Yeah, yeah. And there were a couple of
4 other transformation products that were included in there. But those
5 are the major ones that were included in that.

6 DR. BULL: This is --

7 DR. KENDALL: Dr. Zeise.

8 DR. ZEISE: I was wondering if you could speak to the drinking
9 water consumption assumptions that were made. And then how you
10 dealt with it. If we turn back to the food case, it looks as if a good
11 deal of the high-end exposure coming from perhaps high consumption
12 and high residue levels. And I'm wondering if in this example where
13 the equivalent is sort of trying to address that high-end exposure
14 group.

15 For example, did you address one subgroup that gets basically
16 all it's fluid from water, bottle-fed infant? How did you deal with
17 these more extreme cases?

18 DR. PERFETTI: As part of the food consumption data, the
19 CSFII survey, the latest one, the 94-96 and even the '98 children level,
20 directly asked the question how much water did the individual drink
21 under those two nonconsecutive days. So those consumption values

1 are for water the same type, reflecting the same survey that the foods
2 consumption was collected.

3 DR. ZEISE: Did it capture -- did that sort of capture bottle-fed
4 infant? And did you look at that in particular as a special case where
5 you might have a high exposure? Did you make sure that --

6 DR. PERFETTI: Water consumption of the bottle-fed infant or
7 the formula consumption.

8 DR. ZEISE: Well, you would --

9 DR. PERFETTI: Well, okay. There's two components to water.
10 There's water you get in your food, and there's the water you actually
11 just drink to drink water. Both of those are in the CSFII but in
12 different forms.

13 DR. ZEISE: Okay. Well, I'm just talking about this one
14 particular subpopulation where you might have very high exposure.
15 Do you think they were adequately captured in this analysis?

16 DR. BULL: The extreme would be formula made from water.

17 MS. MULKEY: I thought I understood Dr. Smith as saying --
18 he's here. Do you know the answer to this question, Bill, the formula
19 that you make up, the power the water in the powder formula.

20 DR. SMITH: Yes. As I understand it, the current survey, it
21 breaks out the different forms of water, as Randy was saying; and they

1 are separately listed as water and then there's water that's used in
2 preparing, for example, formula and all the other food components.
3 And it is a fairly high consumption item as you would expect.

4 DR. ZEISE: Okay. Thanks. As we saw earlier this morning,
5 we looked at different plots for different age groups. And in this case,
6 if you think analogously, this might be an age group where you might
7 see -- I mean, it's very upper tail high levels. And I wonder if you did
8 any of that kind of disaggregation to look to see whether there were
9 some subpopulations that could potentially have higher levels, both on
10 a consumption and then from, perhaps, abnormal use applications.

11 DR. PERFETTI: Do you mean in terms of the water?

12 DR. ZEISE: One side the consumption is for the water, and the
13 other side is the different assumptions made with respect to
14 application of pesticide.

15 My understanding is you've used average application that you
16 obtained from surveying. And I don't know the extent to which that
17 might address things like outbreaks and so forth.

18 DR. PERFETTI: I'm not sure I understand all of the question.
19 As far as based on the water consumption and the residues observed
20 from the PRZM-EXAMS run, there was none of the subgroups had --
21 there was hardly any -- well, the MOEs were in order of magnitude

1 above the food and sometimes three or four orders of magnitude. So
2 you will even -- that subgroup zero to one, which, I assume is what
3 you're referring to, that the water was not playing a major part in that
4 even though, as you pointed out, both from water consumption from
5 the formula plus any water the individual drank would be a high
6 consumption of water.

7 MR. COSTELLO: And I think understand what you're getting
8 at when you say "the outbreaks." You're talking about pest pressure
9 and using higher than typical rates. And we choose for the cumulative
10 assessment to use typical, that is to say average rates, where we might
11 not before for individual chemicals because we thought it unlikely that
12 the highest rate for each of the pesticides, for all the pesticides on
13 different crops, would be used at the same time.

14 To attempt to look at -- again, because remember, these are
15 different crops, so pest pressure wouldn't be uniform over all the ones
16 we have in their assemblage. But to attempt to alter some to be higher
17 would introduce another dimension of probabilistic assessment, and it
18 is not something that we attempted.

19 DR. KENDALL: Any further points? Dr. Portier, you stand,
20 then, between the break and closing this session.

21 DR. PORTIER: The average rates question, you answered a

1 question I was going to ask. You didn't consider any variability in
2 what you got out of PRZM-EXAMS. You simply ran it and got sort of
3 an average for each region.

4 MR. THURMAN: Yeah, actually, that was one thing. We held
5 the application rates constant. So what you see in terms of that
6 variability in time is due to weather differences. There was no attempt
7 to try to -- and, actually, part of the problem is with finding the data
8 to do.

9 DR. PORTIER: And the other question, since it's not in front of
10 me and one of the questions you're asking us about, is whether we
11 believe that the water component is a trivial part of the
12 organophosphate exposure. I have to ask the obvious question. How
13 bad were your estimates in the worse case? Since I can't see all the
14 data you looked at in deciding the water concentration levels you
15 observed, give me some indication of the magnitude. Is it less than an
16 order of magnitude? Is it two orders of magnitude?

17 MR. COSTELLO: You mean compared to monitoring.

18 DR. PORTIER: Yes, compared to monitoring data.

19 MR. COSTELLO: I think the important -- I could give you a
20 yes-no answer, but that wouldn't be serving you.

21 In the case of some of the exceedances that were significantly

1 higher and I think they were at somewhere at least an order of
2 magnitude, you have to consider, again, what the monitoring
3 represents. And this is, again, one reason why we couldn't use the
4 monitoring by itself.

5 In looking at the available data, it's an assemblage of
6 monitoring studies designed for different purposes. And some of the
7 highest concentrations that we saw, the best example is an area near
8 Salem, called Solter Creek, from the NAQUA program, where there
9 were several of OPs that exceeded significantly when they came up in
10 our cumulative assessment.

11 But Solter Creek, beyond the fact that it is not a direct drinking
12 water source, also has a small watershed with 99-percent agricultural.
13 Again, a question of scale. The percent-crop-area factors that we
14 come up with are based on OP crops in these large 8-digit HUCs.

15 So to compare what we come up with there to actual monitoring
16 near the time of application in very high-use area in an area that's got
17 99-percent agricultural, we have to actually stop and think what does
18 this mean that it exceeded our output.

19 I mean you have to consider both what does our output really
20 mean, and that's part of one of our questions. And then what does it
21 mean once we figure that out to compare to monitoring with...

1 MR. THURMAN: With those caveats in mind, I can tell you just
2 from going back and going into a little more detail in each of these and
3 figure out what it is.

4 In each of the regions, there's no more than a couple of OPs
5 where we found monitoring that was greater. Most of it was around an
6 order of magnitude type if it was greater. It was not much more than
7 that. And once again, at least as I was doing initializing, you look at
8 once we found our overestimates, first of all we found our
9 underestimates and started taking into account the relative potencies
10 of each of those and looking at that. We didn't see anything that
11 suggested a consistent, you know, that we're missing that by an order
12 by what would effect the assessment by an order of magnitude.

13 I know that's a very general. And I could probably give more
14 details, but I'd have to go back and dig for those.

15 DR. PORTIER: That's fine. I'm not sure you haven't just
16 answered your own question. But when we get to the discussion, I'll
17 do that.

18 The other question is the frequency examples. I didn't get a feel
19 for what's the magnitude of the monitored data in terms of, you know,
20 a given region or a comparison to your model. Are we talking about
21 30 points, 3,000, 20 on an average? Give me some feel for the size of

MR. COSTELLO: The very best monitoring that we might have would be a very small area from the NAQUA program, say, bi-weekly over two years. And that's not common. And on top of that, again, then you have to go deeper. Did that monitoring represent target monitoring for OPs? Was it in a high OP use area? Not usually.

DR. KENDALL: Okay. I'm going to go ahead and close this
ification session. We will take a 15-minute break. When we
rn, we will have two public presentations as registered currently.
then we'll begin the questions at which time the Panel will have
opportunity to address additional issues and concerns.

[Break.]

- 00000 -

1 **CERTIFICATE OF STENOTYPE REPORTER**

2 I, Jane F. Hoffman, Stenotype Reporter, do hereby certify
3 that the foregoing proceedings were reported by me in stenotypy,
4 transcribed under my direction and are a verbatim record of the
5 proceedings had.

6

7

8 -----

9 **JANE F. HOFFMAN**

192

1 **I-N-V-O-I-C-E**** ****I-N-V-O-I-C-E****

2 JANE F. HOFFMAN

3 849 S. Irving Street

4 Arlington, VA 22204

5 SS#305-52-5988

6 TODAY'S DATE: 2/20/02

7 DATE TAKEN: 2/6/02

8 CASE NAME: FIFRA SAP MEETING/PRELIMINARY CUMULATIVE RISK
9 ASSESSMENT

10 **TOTAL: -- PAGES:** 279

11 LOCATION OF DEPO: Arlington, VA

12 DELIVERY: Regular -- conference rate

13